
<!DOCTYPE html>
<html lang="en" >
    <head >

        <meta charset="UTF-8" />
        <meta http-equiv="X-UA-Compatible" content="IE=edge" />
        <meta name="HandheldFriendly" content="True" />
        <meta name="MobileOptimized" content="320" />
        <meta name="viewport" content="width=device-width, initial-scale=1.0" />

        
        

        
        
  <link rel="stylesheet" href="/static/assets/style-8258669d.css" />
<script type="module" crossorigin="" src="/static/assets/base_style-f4a99799.js"></script>

  <link rel="stylesheet" href="/static/assets/style-ef962842.css" />
<link rel="stylesheet" href="/static/assets/style-3ade8b5c.css" />
<script type="module" crossorigin="" src="/static/assets/article_style-d757a0dd.js"></script>

  
  
    <style>
  
  
  @media screen and (min-width: 64em) {
    div.pmc-wm {
      background: repeat-y;
      background-image: url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='20' height='350' xmlns:xlink='http://www.w3.org/1999/xlink'%3E%3Cdefs%3E%3Cfilter x='-.02' y='0' width='1.05' height='1' id='c'%3E%3CfeFlood flood-color='%23FFF'/%3E%3CfeComposite in='SourceGraphic'/%3E%3C/filter%3E%3Ctext id='b' font-family='Helvetica' font-size='11pt' style='opacity:1;fill:%23005ea2;stroke:none;text-anchor:middle' x='175' y='14'%3E%3C/text%3E%3Cpath id='a' style='fill:%23005ea2' d='M0 8h350v3H0z'/%3E%3C/defs%3E%3Cuse xlink:href='%23a' transform='rotate(90 10 10)'/%3E%3Cuse xlink:href='%23b' transform='rotate(90 10 10)' filter='url(%23c)'/%3E%3C/svg%3E");
      padding-left: 3rem;
    }
  }
</style>

  



        
            <link rel="apple-touch-icon"
                  sizes="180x180"
                  href="/static/img/favicons/apple-touch-icon.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="48x48"
                  href="/static/img/favicons/favicon-48x48.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="32x32"
                  href="/static/img/favicons/favicon-32x32.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="16x16"
                  href="/static/img/favicons/favicon-16x16.png" />
            <link rel="manifest" href="/static/img/favicons/site.webmanifest" />
            <link rel="mask-icon"
                  href="/static/img/favicons/safari-pinned-tab.svg"
                  color="#0071bc" />
            <meta name="msapplication-config"
                  content="/static/img/favicons/browserconfig.xml" />
            <meta name="theme-color" content="#ffffff" />
        

        <title>
            Understanding the risk of diabetic retinopathy from glucagon-like peptide-1 receptor agonists: a Mendelian randomization study and systematic review of European populations - PMC
        </title>

        
        
  
  <!-- Logging params: Pinger defaults -->
<meta name="ncbi_app" content="cloudpmc-viewer" />
<meta name="ncbi_db" content="pmc" />
<meta name="ncbi_phid" content="AE5338C08AF310F30538C00028B126F9.m_1" />
<meta name="ncbi_pinger_stat_url" content="https://pmc.ncbi.nlm.nih.gov/stat" />
<!-- Logging params: Pinger custom -->
<meta name="ncbi_pdid" content="article" />
  
    <link rel="preconnect" href="https://www.google-analytics.com" />

    
        <link rel="preconnect" href="https://cdn.ncbi.nlm.nih.gov" />
    

    <!-- Include USWDS Init Script -->
    <script src="/static/assets/uswds-init.js"></script>


    <meta name="ncbi_domain" content="diametsyn">
<meta name="ncbi_type" content="fulltext">
<meta name="ncbi_pcid" content="journal">
<meta name="ncbi_feature" content="associated_data">
<link rel="canonical" href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12366118/">
<meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE">
<meta name="citation_journal_title" content="Diabetology &amp; Metabolic Syndrome">
<meta name="citation_title" content="Understanding the risk of diabetic retinopathy from glucagon-like peptide-1 receptor agonists: a Mendelian randomization study and systematic review of European populations">
<meta name="citation_author" content="Baixuan Shen">
<meta name="citation_author_institution" content="Luoyang Key Laboratory of Clinical Multiomics and Translational Medicine, Henan Key Laboratory of Rare Diseases, Endocrinology and Metabolism Center, The First Affiliated Hospital, and College of Clinical Medicine of Henan, University of Science and Technology, Luoyang, 471003 China">
<meta name="citation_author" content="Wanying Wang">
<meta name="citation_author_institution" content="Luoyang Key Laboratory of Clinical Multiomics and Translational Medicine, Henan Key Laboratory of Rare Diseases, Endocrinology and Metabolism Center, The First Affiliated Hospital, and College of Clinical Medicine of Henan, University of Science and Technology, Luoyang, 471003 China">
<meta name="citation_author" content="Yuanhui Guo">
<meta name="citation_author_institution" content="Luoyang Key Laboratory of Clinical Multiomics and Translational Medicine, Henan Key Laboratory of Rare Diseases, Endocrinology and Metabolism Center, The First Affiliated Hospital, and College of Clinical Medicine of Henan, University of Science and Technology, Luoyang, 471003 China">
<meta name="citation_author" content="Zilong Chen">
<meta name="citation_author_institution" content="Luoyang Key Laboratory of Clinical Multiomics and Translational Medicine, Henan Key Laboratory of Rare Diseases, Endocrinology and Metabolism Center, The First Affiliated Hospital, and College of Clinical Medicine of Henan, University of Science and Technology, Luoyang, 471003 China">
<meta name="citation_author" content="Chuanxin Liu">
<meta name="citation_author_institution" content="Luoyang Key Laboratory of Clinical Multiomics and Translational Medicine, Henan Key Laboratory of Rare Diseases, Endocrinology and Metabolism Center, The First Affiliated Hospital, and College of Clinical Medicine of Henan, University of Science and Technology, Luoyang, 471003 China">
<meta name="citation_author" content="Jiarui Huang">
<meta name="citation_author_institution" content="Department of Internal Medicine, The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology, Luoyang, 471003 China">
<meta name="citation_author" content="Ying Li">
<meta name="citation_author_institution" content="Department of Pharmacy, The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology, Luoyang, 471003 China">
<meta name="citation_publication_date" content="2025 Aug 20">
<meta name="citation_volume" content="17">
<meta name="citation_firstpage" content="345">
<meta name="citation_doi" content="10.1186/s13098-025-01878-3">
<meta name="citation_pmid" content="40830891">
<meta name="citation_abstract_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12366118/">
<meta name="citation_fulltext_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12366118/">
<meta name="citation_pdf_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12366118/pdf/13098_2025_Article_1878.pdf">
<meta name="description" content="Glucagon-like peptide-1 receptor agonists (GLP-1RA) are extensively prescribed to treat obesity and diabetes. However, previous studies have debated whether GLP-1RA use induces diabetic retinopathy (DR) in diabetic populations, and the relationship ...">
<meta name="og:title" content="Understanding the risk of diabetic retinopathy from glucagon-like peptide-1 receptor agonists: a Mendelian randomization study and systematic review of European populations">
<meta name="og:type" content="article">
<meta name="og:site_name" content="PubMed Central (PMC)">
<meta name="og:description" content="Glucagon-like peptide-1 receptor agonists (GLP-1RA) are extensively prescribed to treat obesity and diabetes. However, previous studies have debated whether GLP-1RA use induces diabetic retinopathy (DR) in diabetic populations, and the relationship ...">
<meta name="og:url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12366118/">
<meta name="og:image" content="https://cdn.ncbi.nlm.nih.gov/pmc/cms/images/pmc-card-share.jpg?_=0">
<meta name="twitter:card" content="summary_large_image">
<meta name="twitter:site" content="@ncbi">
    
    

    </head>
    <body >
        
    <a class="usa-skipnav " href="#main-content">
      Skip to main content
    </a>


        
            

<section class="usa-banner " aria-label="Official website of the United States government" >
    <div class="usa-accordion">
        <header class="usa-banner__header">
            <div class="usa-banner__inner">
                <div class="grid-col-auto">
                    <img aria-hidden="true"
                         class="usa-banner__header-flag"
                         src="/static/img/us_flag.svg"
                         alt="" />
                </div>

                <div class="grid-col-fill tablet:grid-col-auto" aria-hidden="true">
                    <p class="usa-banner__header-text">
                        An official website of the United States government
                    </p>
                    <span class="usa-banner__header-action">Here's how you know</span>
                </div>

                



















    
        <button
            type="button"
        
    
    class="usa-accordion__button usa-banner__button
           

           
               
               
               
               
            

           
           
           
           "
    aria-expanded="false"
    aria-controls="gov-banner-default"
    
    data-testid="storybook-django-banner"
    
    >
    
        

        
                    <span class="usa-banner__button-text">Here's how you know</span>
                

        
    
        
            </button>
        


            </div>
        </header>

        <div class="usa-banner__content usa-accordion__content"
             id="gov-banner-default"
             hidden>
            <div class="grid-row grid-gap-lg">
                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-dot-gov.svg"
                         alt=""
                         aria-hidden="true" />
                    <div class="usa-media-block__body">
                        <p>
                            <strong>Official websites use .gov</strong>
                            <br />
                            A
                            <strong>.gov</strong> website belongs to an official
                            government organization in the United States.
                        </p>
                    </div>
                </div>

                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-https.svg"
                         alt=""
                         aria-hidden="true" />

                    <div class="usa-media-block__body">
                        <p>
                            <strong>Secure .gov websites use HTTPS</strong>
                            <br />
                            A <strong>lock</strong> (
                            <span class="icon-lock">
                                <svg xmlns="http://www.w3.org/2000/svg"
                                     width="52"
                                     height="64"
                                     viewBox="0 0 52 64"
                                     class="usa-banner__lock-image"
                                     role="graphics-symbol"
                                     aria-labelledby="banner-lock-description"
                                     focusable="false">
                                    <title id="banner-lock-title">Lock</title>
                                    <desc id="banner-lock-description">
                                    Locked padlock icon
                                    </desc>
                                    <path fill="#000000"
                                          fill-rule="evenodd"
                                          d="M26 0c10.493 0 19 8.507 19 19v9h3a4 4 0 0 1 4 4v28a4 4 0 0 1-4 4H4a4 4 0 0 1-4-4V32a4 4 0 0 1 4-4h3v-9C7 8.507 15.507 0 26 0zm0 8c-5.979 0-10.843 4.77-10.996 10.712L15 19v9h22v-9c0-6.075-4.925-11-11-11z" />
                                </svg>
</span>) or <strong>https://</strong> means you've safely
                                connected to the .gov website. Share sensitive
                                information only on official, secure websites.
                            </p>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </section>

        

        
    
    
    

<div class="usa-overlay">
</div>



<header class="usa-header usa-header--extended usa-header--wide" data-header data-testid="header"    >
    <div class="ncbi-header">
        <div class="ncbi-header__container">
            <a class="ncbi-header__logo-container"
               href="https://www.ncbi.nlm.nih.gov/">
                <img alt="NCBI home page"
                     class="ncbi-header__logo-image"
                     src="/static/img/ncbi-logos/nih-nlm-ncbi--white.svg"
                     width="410"
                     height="100" />
            </a>

            <!-- Mobile menu hamburger button -->
            



















    
        <button
            type="button"
        
    
    class="usa-menu-btn ncbi-header__hamburger-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Show menu"
    data-testid="navMenuButton"
    
    >
    
        

        
                <svg aria-hidden="true"
                     class="ncbi-hamburger-icon"
                     fill="none"
                     focusable="false"
                     height="21"
                     viewBox="0 0 31 21"
                     width="31"
                     xmlns="http://www.w3.org/2000/svg">
                    <path clip-rule="evenodd"
                          d="M0.125 20.75H30.875V17.3333H0.125V20.75ZM0.125 12.2083H30.875V8.79167H0.125V12.2083ZM0.125 0.25V3.66667H30.875V0.25H0.125Z"
                          fill="#F1F1F1"
                          fill-rule="evenodd" />
                </svg>
            

        
    
        
            </button>
        



            
                <!-- Desktop buttons-->
                <div class="ncbi-header__desktop-buttons">
                    
                        <!-- Desktop search button -->
                        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button
           "
    aria-expanded="false"
    aria-controls="search-field-desktop-navigation"
    aria-label="Show search overlay"
    data-testid="toggleSearchPanelButton"
    data-toggle-search-panel-button
    >
    
        

        
                            



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#search" />
    </svg>


                            Search
                        

        
    
        
            </button>
        


                    

                    <!-- Desktop login dropdown -->
                    
                        <div class="ncbi-header__login-dropdown">
                            



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button ncbi-header__login-dropdown-button
           "
    aria-expanded="false"
    aria-controls="login-dropdown-menu"
    aria-label="Show login menu"
    data-testid="toggleLoginMenuDropdown"
    data-desktop-login-button
    >
    
        

        
                                



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#person" />
    </svg>



                                <span data-login-dropdown-text>Log in</span>

                                <!-- Dropdown icon pointing up -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-less ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-up-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_less" />
    </svg>



                                <!-- Dropdown icon pointing down -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-more ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-down-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_more" />
    </svg>


                            

        
    
        
            </button>
        



                            <!-- Login dropdown menu -->
                            <ul class="usa-nav__submenu ncbi-header__login-dropdown-menu"
                                id="login-dropdown-menu"
                                data-desktop-login-menu-dropdown
                                hidden>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                                    </li>
                                
                                <li class="usa-nav__submenu-item">
                                    



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--outline ncbi-header__login-dropdown-logout-button
           "
    
    
    
    data-testid="desktopLogoutButton"
    data-desktop-logout-button
    >
    
        

        Log out

        
    
        
            </button>
        


                                </li>
                            </ul>
                        </div>
                    
                </div>
            
        </div>
    </div>

    <!-- Search panel -->
    
        <div class="ncbi-search-panel ncbi--show-only-at-desktop"
             data-header-search-panel
             hidden>
            <div class="ncbi-search-panel__container">
                <form action="https://www.ncbi.nlm.nih.gov/search/all/"
                      
                      autocomplete="off"
                      class="usa-search usa-search--big ncbi-search-panel__form"
                      data-testid="desktop-navigation-search-form"
                      method="GET"
                      role="search">
                    <label class="usa-sr-only" for="search-field-desktop-navigation">
                        Search…
                    </label>
                    <input class="usa-input"
                           id="search-field-desktop-navigation"
                           name="term"
                           
                               placeholder="Search NCBI"
                           
                           type="search"
                           value="" />
                    



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                        <span class="usa-search__submit-text">
                            Search NCBI
                        </span>
                    

        
    
        
            </button>
        


                </form>

                
            </div>
        </div>
    

    <nav aria-label="Primary navigation" class="usa-nav">
        <p class="usa-sr-only" id="primary-navigation-sr-only-title">
            Primary site navigation
        </p>

        <!-- Mobile menu close button -->
        



















    
        <button
            type="button"
        
    
    class="usa-nav__close ncbi-nav__close-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Close navigation menu"
    data-testid="navCloseButton"
    
    >
    
        

        
            <img src="/static/img/usa-icons/close.svg" alt="Close" />
        

        
    
        
            </button>
        



        
            <!-- Mobile search component -->
            <form class="usa-search usa-search--small ncbi--hide-at-desktop margin-top-6"
                  action="https://www.ncbi.nlm.nih.gov/search/all/"
                  
                  autocomplete="off"
                  data-testid="mobile-navigation-search-form"
                  method="GET"
                  role="search">
                <label class="usa-sr-only" for="search-field-mobile-navigation">
                    Search
                </label>

                <input class="usa-input"
                       id="search-field-mobile-navigation"
                       type="search"
                       
                           placeholder="Search NCBI"
                       
                       name="term" />

                



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                    <!-- This SVG should be kept inline and not replaced with a link to the icon as otherwise it will render in the wrong color -->
                    <img src="data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIGhlaWdodD0iMjQiIHZpZXdCb3g9IjAgMCAyNCAyNCIgd2lkdGg9IjI0Ij48cGF0aCBkPSJNMCAwaDI0djI0SDB6IiBmaWxsPSJub25lIi8+PHBhdGggZmlsbD0iI2ZmZiIgZD0iTTE1LjUgMTRoLS43OWwtLjI4LS4yN0E2LjQ3MSA2LjQ3MSAwIDAgMCAxNiA5LjUgNi41IDYuNSAwIDEgMCA5LjUgMTZjMS42MSAwIDMuMDktLjU5IDQuMjMtMS41N2wuMjcuMjh2Ljc5bDUgNC45OUwyMC40OSAxOWwtNC45OS01em0tNiAwQzcuMDEgMTQgNSAxMS45OSA1IDkuNVM3LjAxIDUgOS41IDUgMTQgNy4wMSAxNCA5LjUgMTEuOTkgMTQgOS41IDE0eiIvPjwvc3ZnPg=="
                         class="usa-search__submit-icon"
                         alt="Search" />
                

        
    
        
            </button>
        


            </form>

            
        

        <!-- Primary navigation menu items -->
        <!-- This usa-nav__inner wrapper is required to correctly style the navigation items on Desktop -->
        

        
            <div class="ncbi-nav__mobile-login-menu ncbi--hide-at-desktop"
                 data-mobile-login-menu
                 hidden>
                <p class="ncbi-nav__mobile-login-menu-status">
                    Logged in as:
                    <strong class="ncbi-nav__mobile-login-menu-email"
                            data-mobile-login-email-text></strong>
                </p>
                <ul class="usa-nav__primary usa-accordion">
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        

        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           ncbi-nav__mobile-login-button ncbi--hide-at-desktop
           "
    
    
    
    data-testid="mobileLoginButton"
    data-mobile-login-button
    >
    
        

        Log in

        
    
        
            </button>
        


    </nav>
</header>

    
    
        

<section class="pmc-header pmc-header--basic" aria-label="PMC Header with search box">
    <div class="pmc-nav-container">
        <div class="pmc-header__bar">
           <div class="pmc-header__logo">
               <a href="/" title="Home" aria-label="PMC Home"></a>
           </div>
            <button
                    type="button"
                    class="usa-button usa-button--unstyled pmc-header__search__button"
                    aria-label="Open search"
                    data-ga-category="search"
                    data-ga-action="PMC"
                    data-ga-label="pmc_search_panel_mobile"
            >
                <svg class="usa-icon width-4 height-4 pmc-icon__open" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#search"></use>
                </svg>
                <svg class="usa-icon width-4 height-4 pmc-icon__close" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
            </button>
        </div>
        <div class="pmc-header__search">
            


<form class="usa-search usa-search--extra usa-search--article-right-column  pmc-header__search__form" id="pmc-search-form" autocomplete="off" role="search">
<label class="usa-sr-only" for="pmc-search">Search PMC Full-Text Archive</label>
<span class="autoComplete_wrapper flex-1">
<input class="usa-input width-full maxw-none" required="required" placeholder="Search PMC Full-Text Archive" id="pmc-search"  type="search" name="term" data-autocomplete-url="https://pmc.ncbi.nlm.nih.gov/autocomp/search/autocomp/"/>
</span>
<button
class="usa-button"
type="submit"
formaction="https://www.ncbi.nlm.nih.gov/pmc/"
data-ga-category="search"
data-ga-action="PMC"
data-ga-label="PMC_search_button"
>
<span class="usa-search__submit-text">Search in PMC</span>
<img
src="/static/img/usa-icons-bg/search--white.svg"
class="usa-search__submit-icon"
alt="Search"
/>
</button>
</form>
            <div class="display-flex flex-column tablet:flex-row tablet:flex-justify flex-justify-center flex-align-center width-full desktop:maxw-44">
                <ul class="pmc-header__search__menu">
                    <li>
                        
                            <a class="usa-link" href="/journals/" data-ga-action="featured_link" data-ga-label="journal list">
                                Journal List
                            </a>
                        
                    </li>
                    <li>
                        
                            <a class="usa-link" href="/about/userguide/" data-ga-action="featured_link"
                            data-ga-label="user guide">
                                User Guide
                            </a>
                        
                    </li>
                </ul>
                
                    <button form="pmc-search-form" formaction="https://pmc.ncbi.nlm.nih.gov/search/" type="submit" class="usa-button usa-button--unstyled hover:text-no-underline text-no-underline width-auto margin-top-1 tablet:margin-top-0">
     <span class="bg-green-label padding-05 text-white">New</span><span class="text-underline text-primary">Try this search in PMC Beta Search</span>
</button>
                
            </div>
        </div>
    </div>
</section>

    


        
        

       
  <div class="usa-section padding-top-0 desktop:padding-top-6 pmc-article-section" data-article-db="pmc" data-article-id="12366118">

    

   



<div class="grid-container pmc-actions-bar" aria-label="Actions bar" role="complementary">
    <div class="grid-row">
        <div class="grid-col-fill display-flex">
             <div class="display-flex">
                <ul class="usa-list usa-list--unstyled usa-list--horizontal">
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <button
                                type="button"
                                class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                                aria-label="Open resources"
                                data-extra-class="is-visible-resources"
                                data-ga-category="resources_accordion"
                                data-ga-action="click"
                                data-ga-label="mobile_icon"
                        >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#more_vert"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <a
                                href="https://doi.org/10.1186/s13098-025-01878-3"
                                class="usa-link display-flex usa-tooltip"
                                role="button"
                                target="_blank"
                                rel="noreferrer noopener"
                                title="View on publisher site"
                                data-position="bottom"
                                aria-label="View on publisher site"
                                data-ga-category="actions"
                                data-ga-action="click"
                                data-ga-label="publisher_link_mobile"
                        >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#launch"></use>
                                </svg>
                        </a>
                    </li>
                    
                    
                        <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                             <a
                                     href="pdf/13098_2025_Article_1878.pdf"
                                     class="usa-link display-flex usa-tooltip"
                                     role="button"
                                     title="Download PDF"
                                     data-position="bottom"
                                     aria-label="Download PDF"
                                     data-ga-category="actions"
                                     data-ga-action="click"
                                     data-ga-label="pdf_download_mobile"
                             >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                                </svg>
                            </a>
                        </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button
                            class="usa-button usa-button--unstyled  usa-tooltip collections-dialog-trigger collections-button display-flex collections-button-empty"
                            title="Add to Collections"
                            data-position="bottom"
                            aria-label="Save article in MyNCBI collections."
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="collections_button_mobile"
                            data-collections-open-dialog-enabled="false"
                            data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12366118%2F%3Freport%3Dclassic%23open-collections-dialog"
                            data-in-collections="false"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button role="button" class="usa-button usa-button--unstyled usa-tooltip citation-dialog-trigger display-flex"
                            aria-label="Open dialog with citation text in different styles"
                            title="Cite"
                            data-position="bottom"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="cite_mobile"
                            data-all-citations-url="/resources/citations/12366118/"
                            data-citation-style="nlm"
                            data-download-format-link="/resources/citations/12366118/export/"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="pmc-permalink display-flex" >
                         <button
                                 type="button"
                                 title="Permalink"
                                 data-position="bottom"
                                 class="usa-button usa-button--unstyled display-flex usa-tooltip"
                                 aria-label="Show article permalink"
                                 aria-expanded="false"
                                 aria-haspopup="true"
                                 data-ga-category="actions"
                                 data-ga-action="open"
                                 data-ga-label="permalink_mobile"
                         >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#share"></use>
                            </svg>
                        </button>
                        

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12366118/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
                    </li>
                </ul>
            </div>
            <button
                    type="button"
                    class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                    aria-label="Open article navigation"
                    data-extra-class="is-visible-in-page"
                    data-ga-category="actions"
                    data-ga-action="open"
                    data-ga-label="article_nav_mobile"
            >
                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#list"></use>
                </svg>
            </button>
        </div>
    </div>
</div>
    <div class="grid-container desktop:padding-left-6">
      <div id="article-container" class="grid-row grid-gap">
        <div class="grid-col-12 desktop:grid-col-8 order-2 pmc-layout__content">
            <div class="grid-container padding-left-0 padding-right-0">
                <div class="grid-row desktop:margin-left-neg-6">
                    <div class="grid-col-12">
                        <div class="pmc-layout__disclaimer" role="complementary" aria-label="Disclaimer note">
    As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with,
    the contents by NLM or the National Institutes of Health.<br/>
    Learn more:
    <a class="usa-link" data-ga-category="Link click" data-ga-action="Disclaimer" data-ga-label="New disclaimer box" href="/about/disclaimer/">PMC Disclaimer</a>
    |
    <a class="usa-link" data-ga-category="Link click" data-ga-action="PMC Copyright Notice" data-ga-label="New disclaimer box" href="/about/copyright/">
        PMC Copyright Notice
    </a>
</div>
                    </div>
                </div>
                <div class="grid-row pmc-wm desktop:margin-left-neg-6">
                    <!-- Main content -->
                    <main
                      id="main-content"
                      class="usa-layout-docs__main usa-layout-docs grid-col-12 pmc-layout pmc-prose padding-0"
                    >

                      
                        <section class="pmc-journal-banner text-center line-height-none" aria-label="Journal banner"><img src="https://cdn.ncbi.nlm.nih.gov/pmc/banners/logo-diametsyn.png" alt="Diabetology &amp; Metabolic Syndrome logo" usemap="#pmc-banner-imagemap" width="500" height="75"><map name="pmc-banner-imagemap"><area alt="Link to Diabetology &amp; Metabolic Syndrome" title="Link to Diabetology &amp; Metabolic Syndrome" shape="default" href="https://dmsjournal.biomedcentral.com/" target="_blank" rel="noopener noreferrer"></map></section><article lang="en"><section aria-label="Article citation and metadata"><section class="pmc-layout__citation font-secondary font-xs"><div>
<div class="display-inline-block"><button type="button" class="cursor-pointer text-no-underline bg-transparent border-0 padding-0 text-left margin-0 text-normal text-primary" aria-controls="journal_context_menu">Diabetol Metab Syndr</button></div>. 2025 Aug 20;17:345. doi: <a href="https://doi.org/10.1186/s13098-025-01878-3" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">10.1186/s13098-025-01878-3</a>
</div>
<nav id="journal_context_menu" hidden="hidden"><ul class="menu-list font-family-ui" role="menu">
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/pmc/?term=%22Diabetol%20Metab%20Syndr%22%5Bjour%5D" class="usa-link" role="menuitem">Search in PMC</a></li>
<li role="presentation"><a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Diabetol%20Metab%20Syndr%22%5Bjour%5D" lang="en" class="usa-link" role="menuitem">Search in PubMed</a></li>
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Diabetol%20Metab%20Syndr%22%5BTitle%20Abbreviation%5D" class="usa-link" role="menuitem">View in NLM Catalog</a></li>
<li role="presentation"><a href="?term=%22Diabetol%20Metab%20Syndr%22%5Bjour%5D" class="usa-link" role="menuitem" data-add-to-search="true">Add to search</a></li>
</ul></nav></section><section class="front-matter"><div class="ameta p font-secondary font-xs">
<hgroup><h1>Understanding the risk of diabetic retinopathy from glucagon-like peptide-1 receptor agonists: a Mendelian randomization study and systematic review of European populations</h1></hgroup><div class="cg p">
<a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Shen%20B%22%5BAuthor%5D" class="usa-link" aria-describedby="id1"><span class="name western">Baixuan Shen</span></a><div hidden="hidden" id="id1">
<h3><span class="name western">Baixuan Shen</span></h3>
<div class="p">
<sup>1</sup>Luoyang Key Laboratory of Clinical Multiomics and Translational Medicine, Henan Key Laboratory of Rare Diseases, Endocrinology and Metabolism Center, The First Affiliated Hospital, and College of Clinical Medicine of Henan, University of Science and Technology, Luoyang, 471003 China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Shen%20B%22%5BAuthor%5D" class="usa-link"><span class="name western">Baixuan Shen</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Wang%20W%22%5BAuthor%5D" class="usa-link" aria-describedby="id2"><span class="name western">Wanying Wang</span></a><div hidden="hidden" id="id2">
<h3><span class="name western">Wanying Wang</span></h3>
<div class="p">
<sup>1</sup>Luoyang Key Laboratory of Clinical Multiomics and Translational Medicine, Henan Key Laboratory of Rare Diseases, Endocrinology and Metabolism Center, The First Affiliated Hospital, and College of Clinical Medicine of Henan, University of Science and Technology, Luoyang, 471003 China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Wang%20W%22%5BAuthor%5D" class="usa-link"><span class="name western">Wanying Wang</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Guo%20Y%22%5BAuthor%5D" class="usa-link" aria-describedby="id3"><span class="name western">Yuanhui Guo</span></a><div hidden="hidden" id="id3">
<h3><span class="name western">Yuanhui Guo</span></h3>
<div class="p">
<sup>1</sup>Luoyang Key Laboratory of Clinical Multiomics and Translational Medicine, Henan Key Laboratory of Rare Diseases, Endocrinology and Metabolism Center, The First Affiliated Hospital, and College of Clinical Medicine of Henan, University of Science and Technology, Luoyang, 471003 China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Guo%20Y%22%5BAuthor%5D" class="usa-link"><span class="name western">Yuanhui Guo</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Chen%20Z%22%5BAuthor%5D" class="usa-link" aria-describedby="id4"><span class="name western">Zilong Chen</span></a><div hidden="hidden" id="id4">
<h3><span class="name western">Zilong Chen</span></h3>
<div class="p">
<sup>1</sup>Luoyang Key Laboratory of Clinical Multiomics and Translational Medicine, Henan Key Laboratory of Rare Diseases, Endocrinology and Metabolism Center, The First Affiliated Hospital, and College of Clinical Medicine of Henan, University of Science and Technology, Luoyang, 471003 China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Chen%20Z%22%5BAuthor%5D" class="usa-link"><span class="name western">Zilong Chen</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Liu%20C%22%5BAuthor%5D" class="usa-link" aria-describedby="id5"><span class="name western">Chuanxin Liu</span></a><div hidden="hidden" id="id5">
<h3><span class="name western">Chuanxin Liu</span></h3>
<div class="p">
<sup>1</sup>Luoyang Key Laboratory of Clinical Multiomics and Translational Medicine, Henan Key Laboratory of Rare Diseases, Endocrinology and Metabolism Center, The First Affiliated Hospital, and College of Clinical Medicine of Henan, University of Science and Technology, Luoyang, 471003 China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Liu%20C%22%5BAuthor%5D" class="usa-link"><span class="name western">Chuanxin Liu</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Huang%20J%22%5BAuthor%5D" class="usa-link" aria-describedby="id6"><span class="name western">Jiarui Huang</span></a><div hidden="hidden" id="id6">
<h3><span class="name western">Jiarui Huang</span></h3>
<div class="p">
<sup>2</sup>Department of Internal Medicine, The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology, Luoyang, 471003 China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Huang%20J%22%5BAuthor%5D" class="usa-link"><span class="name western">Jiarui Huang</span></a>
</div>
</div>
<sup>2,</sup><sup>✉</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Li%20Y%22%5BAuthor%5D" class="usa-link" aria-describedby="id7"><span class="name western">Ying Li</span></a><div hidden="hidden" id="id7">
<h3><span class="name western">Ying Li</span></h3>
<div class="p">
<sup>3</sup>Department of Pharmacy, The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology, Luoyang, 471003 China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Li%20Y%22%5BAuthor%5D" class="usa-link"><span class="name western">Ying Li</span></a>
</div>
</div>
<sup>3,</sup><sup>✉</sup>
</div>
<ul class="d-buttons inline-list">
<li><button class="d-button" aria-controls="aip_a" aria-expanded="false">Author information</button></li>
<li><button class="d-button" aria-controls="anp_a" aria-expanded="false">Article notes</button></li>
<li><button class="d-button" aria-controls="clp_a" aria-expanded="false">Copyright and License information</button></li>
</ul>
<div class="d-panels font-secondary-light">
<div id="aip_a" class="d-panel p" style="display: none">
<div class="p" id="Aff1">
<sup>1</sup>Luoyang Key Laboratory of Clinical Multiomics and Translational Medicine, Henan Key Laboratory of Rare Diseases, Endocrinology and Metabolism Center, The First Affiliated Hospital, and College of Clinical Medicine of Henan, University of Science and Technology, Luoyang, 471003 China </div>
<div id="Aff2">
<sup>2</sup>Department of Internal Medicine, The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology, Luoyang, 471003 China </div>
<div id="Aff3">
<sup>3</sup>Department of Pharmacy, The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology, Luoyang, 471003 China </div>
<div class="author-notes p"><div class="fn" id="_fncrsp93pmc__">
<sup>✉</sup><p class="display-inline">Corresponding author.</p>
</div></div>
</div>
<div id="anp_a" class="d-panel p" style="display: none"><div class="notes p"><section id="historyarticle-meta1" class="history"><p>Received 2025 Feb 11; Accepted 2025 Jul 25; Collection date 2025.</p></section></div></div>
<div id="clp_a" class="d-panel p" style="display: none">
<div>© The Author(s) 2025</div>
<p><strong>Open Access</strong> This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <a href="https://creativecommons.org/licenses/by-nc-nd/4.0/" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">http://creativecommons.org/licenses/by-nc-nd/4.0/</a>.</p>
<div class="p"><a href="/about/copyright/" class="usa-link">PMC Copyright notice</a></div>
</div>
</div>
<div>PMCID: PMC12366118  PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40830891/" class="usa-link">40830891</a>
</div>
</div></section></section><section aria-label="Article content"><section class="body main-article-body"><section class="abstract" id="Abs1"><h2>Abstract</h2>
<section id="sec1"><h3 class="pmc_sec_title">Background</h3>
<p id="Par1">Glucagon-like peptide-1 receptor agonists (GLP-1RA) are extensively prescribed to treat obesity and diabetes. However, previous studies have debated whether GLP-1RA use induces diabetic retinopathy (DR) in diabetic populations, and the relationship between the two is unclear.</p></section><section id="sec2"><h3 class="pmc_sec_title">Methods</h3>
<p id="Par2">Cis-expressed quantitative trait locus data (Cis-eQTL) in blood tissue were used to extract single nucleotide polymorphisms (SNPs) as a genetic proxy tool. The analyses were performed using Mendelian randomisation (MR) as the primary tool and Summary-data-based Mendelian Randomization (SMR) as an auxiliary validation. Discovery cohort was obtained from a large study from the GWAS catalog database, and the FinnGen consortium DR data were used as a validation cohort. Additionally, the outcomes of the two cohorts were combined using meta-analysis. In addition, we systematically retrieved relevant cohort studies of GLP-1RA and DR for systematic review to complement the association of GLP-1RA with DR in the real world.</p></section><section id="sec3"><h3 class="pmc_sec_title">Results</h3>
<p id="Par3">A total of 9 SNPs highly correlated with the exposure were screened as tool variables to proxy for GLP-1RA. The MR method showed a significant association between GLP-1RA and reduced risk of DR (OR = 0.59, 95%CI: 0.39–0.89, <em>P</em> = 0.0109), in addition, similar results were also found with the SMR method (OR = 0.48, 95%CI: 0.27–0.86, <em>P</em> = 0.0129). Finally, a total of three eligible articles were included in the systematic review, and overall GLP-1RA reduces the incidence of DR compared with existing glucose-lowering agents, but more research is required to verify the generalisability of the findings.</p></section><section id="sec4"><h3 class="pmc_sec_title">Conclusion</h3>
<p id="Par4">Based on MR and SMR, we found that GLP-1RA can reduce the risk of DR. Systematic review showed that compared with insulin therapy, T2D patients treated with GLP-1RA had a lower incidence of DR, but compared with other hypoglycemic agents, the incidence of DR was inconsistent. Therefore, clinical trials with larger sample sizes and longer follow-up times are warranted to determine this.</p></section><section id="sec5"><h3 class="pmc_sec_title">Supplementary Information</h3>
<p>The online version contains supplementary material available at 10.1186/s13098-025-01878-3.</p></section><section id="kwd-group1" lang="en" class="kwd-group"><p><strong>Keywords:</strong> GLP-1R agonist, Diabetic retinopathy, Mendelian randomization, Single nucleotide polymorphisms, Genome-wide association studies</p></section></section><section id="Sec1"><h2 class="pmc_sec_title">Introduction</h2>
<p id="Par5">Globally, the number of people with diabetes continues to increase quickly due to a combination of hereditary and environmental factors, with some research claiming that diabetes may influence almost 693 million people globally by the year 2045. However, common microvascular complications such as the threatening diabetic retinopathy (DR) have not only exacerbated the condition of diabetic patients but also significantly reduced their prognosis, and by 2020, the number of people with DR had exceeded 100 million globally, and is still on the rise [<a href="#CR1" class="usa-link" aria-describedby="CR1">1</a>, <a href="#CR2" class="usa-link" aria-describedby="CR2">2</a>]. Although medications for diabetes mellitus have been updated and evolved in recent years, it is not clear whether the use of these drugs in patients with diabetes induces DR, therefore, it is especially crucial to thoroughly examine the safety of these drugs.</p>
<p id="Par6">As a leading medication approved by the U.S. Food and Drug Administration (FDA) for the treatment of individuals with type 2 diabetes (T2D) and obesity, glucagon-like peptide-1 receptor agonists (GLP-1RAs) such as semaglutide and liraglutide significantly improved body weight in patients with T2D while reducing glycated haemoglobin (HbA1c) levels in these patients [<a href="#CR3" class="usa-link" aria-describedby="CR3">3</a>, <a href="#CR4" class="usa-link" aria-describedby="CR4">4</a>]. Moreover, in the Multicentre Long-Term Cardiovascular Outcomes Trial, GLP-1RA decreased all-cause mortality, vascular mortality and non-fatal heart attacks in participants [<a href="#CR5" class="usa-link" aria-describedby="CR5">5</a>]. It is worth noting that despite the potential benefits of GLP-1RA, evidence from the SUSTAIN-6 clinical trial suggests that GLP-1RA may be a risk factor for DR, whereas the clinical trial from LEADER demonstrated that the two are not related [<a href="#CR1" class="usa-link" aria-describedby="CR1">1</a>, <a href="#CR6" class="usa-link" aria-describedby="CR6">6</a>]. As a result, it is crucial to investigate the precise relationship between GLP-1RA and DR using innovative research techniques.</p>
<p id="Par7">As genome-wide association studies (GWAS) continue to evolve, the Mendelian randomisation (MR) method provides a novel perspective on the study of causality between two traits from a genetic direction. MR is a method that employs single nucleotide polymorphisms (SNPs) related to clinical phenotypes as tool variables to probe underlying causality between exposures and outcomes of interest [<a href="#CR7" class="usa-link" aria-describedby="CR7">7</a>]. Furthermore, based on MR, Yang et al. [<a href="#CR8" class="usa-link" aria-describedby="CR8">8</a>] created the Summary-data-based Mendelian randomisation (SMR) method and the related instrumental heterogeneity test (HEIDI) method for assessing the robustness of SMR results, a great achievement that enriched the use of MR method further. In conclusion, compared with existing observational studies, MR with SMR simulates the process of random assignment of parental alleles to offspring, and thus can effectively reduce confounding-induced bias and enhance causal inferences [<a href="#CR7" class="usa-link" aria-describedby="CR7">7</a>].</p>
<p id="Par8">Consequently, in the context of this research, we used cis-expression quantitative trait locus (Cis-eQTL) data of the GLP-1R gene in blood tissues instead of GLP-1RA and assessed the risk association between GLP-1R gene expression and DR using MR as the primary analytical method while referring to the auxiliary analytical results of the SMR method, and to reduce the bias introduced by caste, we limited the participants to be of European origin. We also systematically searched for cohort studies based on European populations to further analyse the association between GLP-1RA and DR in the real world.</p></section><section id="Sec2"><h2 class="pmc_sec_title">Materials and methods</h2>
<section id="Sec3"><h3 class="pmc_sec_title">Research design</h3>
<p id="Par9">A drug-targeted Mendelian randomisation approach was utilised to investigate the causal link between increased GLP-1R gene expression and DR in European populations using SNP pooled data of the GLP-1R gene as an instrumental variable. In addition, we used GWAS data of HbA1c, T2D for double positive control to test whether the instrumental variables were representative and reliable. Meanwhile, we used European population data from two different databases as a discovery cohort and a validation cohort to analyse the association of instrumental variables with DR, respectively. In addition, to reduce the bias caused by the data sources and to improve the statistical efficacy, we performed Meta-analysis of the two results with the total effect as the final result. The SMR method was used in our auxiliary analyses to test the accuracy of the results. Finally, we comprehensively searched and reviewed clinical cohort studies based on European populations to complement the real-world risk associations between GLP-1RA and DR. Its research process is shown in Fig. <a href="#Fig1" class="usa-link">1</a>. The data used in this paper were obtained from publicly available databases and written with reference to STROBE-MR, so there are no ethical issues or conflicts of interest.</p>
<figure class="fig xbox font-sm" id="Fig1"><h4 class="obj_head">Fig. 1.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12366118_13098_2025_1878_Fig1_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8591/12366118/bbd37c7e587a/13098_2025_1878_Fig1_HTML.jpg" loading="lazy" id="d33e271" height="1015" width="687" alt="Fig. 1"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig1/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Flowchart of the study design. Stage1 is the MR/SMR analysis process, and Stage2 is the PRISMA flowchart for a systematic review</p></figcaption></figure></section><section id="Sec4"><h3 class="pmc_sec_title">Mendelian randomisation analysis method</h3>
<section id="Sec5"><h4 class="pmc_sec_title">Single nucleotide polymorphism instrumental variable screening</h4>
<p id="Par11">The eQTLGen Consortium [<a href="#CR9" class="usa-link" aria-describedby="CR9">9</a>] (<a href="http://www.eqtlgen.org" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">www.eqtlgen.org</a>) contains blood gene eQTL data from 31,684 human individuals, providing a new platform for the investigation of the correlation between gene expression and inheritance. Therefore, we used GLP-1RA as an exposure factor, and Cis-eQTL summary data (chromosome: 6; gene region: 39016557-1000 kb-39059079 + 1000 kb) from the eQTLGen Consortium for SNPs in the target gene GLP-1R were selected as instrumental variables for genetic proxies. To obtain more robust instrumental variables to improve statistical efficacy, and to fulfil the requirement that instrumental variables are strongly correlated with exposure, we included SNPs with <em>P</em> &lt; 1 × 10<sup>− 5</sup> for further screening [<a href="#CR10" class="usa-link" aria-describedby="CR10">10</a>]. Taking into account the effect of linkage disequilibrium (LD) on the results, a genetically independent SNP clumping threshold of r<sup>2</sup> &lt; 0.3 was set based on the 1,000 Genomes European Population dataset with a window of 10,000 kb, and an F-statistic (beta<sup>2</sup>/se<sup>2</sup>) &gt; 10 was used as the criterion for strongly correlated instrumental variables. In addition, minor allele frequency (MAF) &gt; 0.01 is considered a common rather than rare variant and was also used as a screening criterion for SNPs [<a href="#CR11" class="usa-link" aria-describedby="CR11">11</a>]. The LDlink website [<a href="#CR12" class="usa-link" aria-describedby="CR12">12</a>] (<a href="https://ldlink.nci.nih.gov" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://ldlink.nci.nih.gov</a>) provides information on confounding traits such as smoking, alcohol consumption, and obesity that are associated with the traits under study. We used this website to query confounders for SNPs and excluded instrumental variables that clearly had confounding effects on outcomes to reduce bias due to confounders.</p></section><section id="Sec6"><h4 class="pmc_sec_title">Instrumental variable double positive control validation</h4>
<p id="Par12">To validate the validity and reliability of the instrumental variables, we extracted data from two large authoritative databases for double-positive control analyses. The UK Biobank database [<a href="#CR13" class="usa-link" aria-describedby="CR13">13</a>] (<a href="http://www.ukbiobank.ac.uk" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">www.ukbiobank.ac.uk</a>) collects information on whole genome sequence data, health data, and life data for nearly half a million adult UK residents from 2006 to 2010 and reports the participants’ baseline data characteristics. We obtained HbA1c genetic association data (Code:30750) from this database for 344,182 participants as the first positive control outcome. The DIAGRAM Consortium database (<a href="http://www.diagram-consortium.org" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">www.diagram-consortium.org</a>) contains a large number of GWAS data on patients with T2D, and we acquired the T2D data as a second positive control endpoint from a large meta-analysis of this database that included 80,154 European patients and 853,816 European normal populations [<a href="#CR14" class="usa-link" aria-describedby="CR14">14</a>]. Causal associations of instrumental variables with the two outcomes were analysed using a two-sample MR approach.</p></section><section id="Sec7"><h4 class="pmc_sec_title">DR data collection</h4>
<p id="Par13">Discovery cohort data were extracted from the GWAS catalog database (<a href="http://www.ebi.ac.uk/gwas/" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">www.ebi.ac.uk/gwas/</a>) of a UK population-based GWAS information of 1,339 DR patients and 396,859 controls (Code: GCST90435714) [<a href="#CR15" class="usa-link" aria-describedby="CR15">15</a>]. In addition, to further test the reliability of the results and to reduce the error due to sample overlap, we performed validation using the latest data from the FinnGen (<a href="http://www.finngen.fi" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">www.finngen.fi</a>) database, version R11. The data of the selected validation cohort contained 3,283 patients and 71,585 controls (Code: DM_RETINOPATHY_STRICT). Both of the above DR datasets meet the definition of ICD-10. The relationship between all the loci of the chromosomes of the two datasets and their corresponding <em>P</em>-values is shown in the Manhattan plot, the red dotted line stands for <em>P</em> = 1e-5 (Fig. <a href="#Fig2" class="usa-link">2</a>).</p>
<figure class="fig xbox font-sm" id="Fig2"><h5 class="obj_head">Fig. 2.</h5>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12366118_13098_2025_1878_Fig2_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8591/12366118/2a94d493286f/13098_2025_1878_Fig2_HTML.jpg" loading="lazy" id="d33e369" height="937" width="744" alt="Fig. 2"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig2/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Manhattan plot of DR’s GWAS data. The abscissa indicates the chromosome position where the SNP is located, the ordinate indicates the <em>P</em>-value corresponding to the SNP, and the red line represents the threshold <em>P</em> = 1e-5. (A) GWAS data from the Manhattan plot of the GWAS catalog database. (B) Manhattan plot of GWAS data from FinnGen database</p></figcaption></figure></section><section id="Sec8"><h4 class="pmc_sec_title">MR analysis</h4>
<p id="Par15">Since the random-effects inverse variance weighting (IVW) analysis is more accurate and robust [<a href="#CR16" class="usa-link" aria-describedby="CR16">16</a>], this study used random-effects IVW as the main analysis method to compute the odds ratio (OR) and its 95% confidence intervals, and four methods, namely, MR-Egger regression, Weighted median, Simple mode, Weighted mode as reference. Bayesian Weighted Mendelian Randomization (BWMR) was first proposed by Zhao et al. in 2019. It introduces weighted strategies through a Bayesian framework and systematically integrates pleiotropy modelling to address the pleiotropy issues inherent in traditional MR methods [<a href="#CR17" class="usa-link" aria-describedby="CR17">17</a>]. In this study, the BWMR model is introduced as a supplementary analysis to MR methods. Finally, we pooled the MR results from the two databases by Meta-analysis to enhance the statistical efficacy. The analysis was conducted utilizing the ‘TwoSampleMR’ package and ‘BWMR’ package within R software (version 4.3.3). We used the Bonferroni method for multiple corrections and considered <em>P</em> &lt; 0.025 (0.05/2, 2 representing outcomes from both databases) to be statistically significant, whereas <em>P</em> &lt; 0.05 was regarded as indicative of a possible causative relationship [<a href="#CR18" class="usa-link" aria-describedby="CR18">18</a>].</p>
<p id="Par16">Furthermore, a series of sensitivity analyses were performed to evaluate the robustness of the findings, including: (1) Cochran Q test using the IVW method and MR-Egger regression was used to analyze the magnitude of heterogeneity (<em>P</em> &lt; 0.05 indicated that there was a large degree of heterogeneity). (2) Horizontal pleiotropy test using the MR-Egger intercept method and MR-PRESSO Global test for selected instrumental variables (<em>P</em> &lt; 0.05 considered that horizontal pleiotropy exists, when other potential pathways due to non-exposure routes may influence the outcome).(3) The MR-PRESSO outlier test was used to determine the presence of outlier SNPs (<em>P</em> &lt; 0.05 indicated the presence of outliers), and the leave-one-out method was used to observe the effect of individual SNPs on the results by excluding SNPs one by one, in order to assess the presence of SNPs that significantly contribute to the bias of the results. The above process was done using the ‘TwoSampleMR’ and ‘MR-PRESSO’ packages.</p>
<p id="Par17">In addition to sensitivity analyses, we performed co-localisation analyses using the ‘coloc’ package of the R software to assess whether the two phenotypes were mediated by the same genetic variants. In this study, we set the cis region of GLP-1R gene as the co-localisation region (including a total of 235 SNPs), and the tacit a prior probabilities were P1 = 1e-4, P2 = 1e-4 and P12 = 1e-5 (P1, P2 and P12 are the probabilities of SNPs in the co-localisation region with significant chain relationship with the gene expression, the risk of DR, and the two) [<a href="#CR19" class="usa-link" aria-describedby="CR19">19</a>]. Finally, the posterior probability (PP) was obtained from the co-localization analysis and the hypothesis (H0-H4) was judged according to PP. (H0: There was no genetic linkage of the two traits in this region; H1: Only one trait is genetically linked in this region; H2: There is only one additional attribute that is genetically associated with this region; H3: The two traits are related but have different causal variations; H4: Both traits are mediated by identical cause and effect variants)</p></section><section id="Sec9"><h4 class="pmc_sec_title">SMR-assisted analysis</h4>
<p id="Par18">The SMR approach, which uses pooled data from GWAS and eQTL for analyses, can to some extent reflect associations between gene expression levels and traits of interest, so we used the SMR approach as an auxiliary analysis to further complement the MR results. We selected 1000 Genomes European population data as the LD reference information, SNPs with <em>P</em> &lt; 1 × 10<sup>− 5</sup> in the cis region of the GLP-1R gene from the eQTLGen Consortium database as the instrumental variable dataset, and utilised the previously selected DR datasets from the GWAS catalog and FinnGen databases as the outcome. As this study used the SMR method for two hypothesis tests (DR data from both databases), after the Bonferroni method of correcting for multiplicity, it was considered that <em>P</em> &lt; 0.025 (0.05/2) represented evidence of significance. In addition, we performed a HEIDI test to assess whether the association was mediated by pleiotropy and LD (<em>P</em> &lt; 0.05 indicates unreliable results). All the above procedures were done based on SMR software (version 1.3.1).</p></section></section><section id="Sec10"><h3 class="pmc_sec_title">Systematic review of clinical cohort studies</h3>
<section id="Sec11"><h4 class="pmc_sec_title">The article selection criteria and retrieval strategy</h4>
<p id="Par19">To gain a more comprehensive understanding of the association between GLP-1RA and DR, we systematically searched Pubmed (<a href="https://pubmed.ncbi.nlm.nih.gov" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://pubmed.ncbi.nlm.nih.gov</a>), Embase (<a href="http://www.embase.com" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">www.embase.com</a>) and Cochrane library (<a href="http://www.cochranelibrary.com" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">www.cochranelibrary.com</a>) databases and set the below included and excluded standards with reference to the PRISMA flowchart. Inclusion criteria: (1) Study type: cohort study. Because cohort studies are more consistent with the causal relationship of the etiological chain and have a high degree of argumentation [<a href="#CR20" class="usa-link" aria-describedby="CR20">20</a>]. (2) Study population: European adult population with diabetes (including type 1 and type 2 diabetes). (3) Intervention: GLP-1RA in the exposed group and placebo or other glucose-lowering agents in the controls. (4) Outcome indicators: whether DR occurred or not. Exclusion criteria: non-English language literature, duplicate publications, literature with inaccessible information, incomplete data, and literature from non-European populations.</p>
<p id="Par20">According to the above inclusion and exclusion criteria, we formulated a search strategy combining free and Medical Subject Headings (MeSH) terms, both of which were retrieved from database construction to 14 August 2024. Details of the search strategies have been shown in Supplementary Table <a href="#MOESM1" class="usa-link">1</a>.</p></section><section id="Sec12"><h4 class="pmc_sec_title">Selection of articles and quality assessment and information extraction</h4>
<p id="Par21">2 researchers (Shen and Wang) independently sifted the documents, abstracted the information and cross-checked it. Controversial issues were discussed or consulted with a third party for resolution. Data extracted included: first author, year of publication, type of study design, country, sample size, age, period of study, length of follow-up, number of people exposed and unexposed, outcome indicators of interest, and outcome data. In addition, risk of bias was assessed for the screened documents using the Newcastle-Ottawa Scale (NOS), with outcomes expressed as scores.</p></section></section></section><section id="Sec13"><h2 class="pmc_sec_title">Results</h2>
<section id="Sec14"><h3 class="pmc_sec_title">Information on instrumental variables of genetic agents</h3>
<p id="Par22">Within the cis region of the GLP-1R gene, we extracted a total of 235 SNPs from the eQTLGen Consortium (Supplementary Table <a href="#MOESM2" class="usa-link">2</a>), and screened 10 SNPs that were prominently linked to exposure factors with a threshold value of <em>P</em> &lt; 1 × 10<sup>− 5</sup> to serve as genetic proxies for the GLP-1R gene (see Supplementary Table <a href="#MOESM3" class="usa-link">3</a> for more information). Nevertheless, upon searching for confounders on the LDlink website, we found that the ‘rs10305420’ tool variable was related to the smoking trait, which is regarded as a DR risk factor [<a href="#CR21" class="usa-link" aria-describedby="CR21">21</a>], and thus we excluded this tool variable to reduce its interference with the results. Table <a href="#Tab1" class="usa-link">1</a> shows the data of 9 SNPs that were finally included and all of them had MAF &gt; 0.01 and F-statistic &gt; 10, which demonstrated that no bias caused by weak tool variables was present in our study.</p>
<section class="tw xbox font-sm" id="Tab1"><h4 class="obj_head">Table 1.</h4>
<div class="caption p"><p>Information on GLP-1RA instrumental variables for genetic agents</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<thead><tr>
<th align="left" colspan="1" rowspan="1">SNP</th>
<th align="left" colspan="1" rowspan="1">CHR</th>
<th align="left" colspan="1" rowspan="1">EA</th>
<th align="left" colspan="1" rowspan="1">OA</th>
<th align="left" colspan="1" rowspan="1">
<em>P</em>
</th>
<th align="left" colspan="1" rowspan="1">Beta</th>
<th align="left" colspan="1" rowspan="1">Se</th>
<th align="left" colspan="1" rowspan="1">MAF</th>
<th align="left" colspan="1" rowspan="1">F</th>
</tr></thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1">rs1018437</td>
<td align="center" colspan="1" rowspan="1">6</td>
<td align="left" colspan="1" rowspan="1">C</td>
<td align="left" colspan="1" rowspan="1">T</td>
<td align="left" colspan="1" rowspan="1">2.02E-13</td>
<td align="center" colspan="1" rowspan="1">-0.061</td>
<td align="center" colspan="1" rowspan="1">0.008</td>
<td align="center" colspan="1" rowspan="1">0.437</td>
<td align="center" colspan="1" rowspan="1">53.989</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">rs10305439</td>
<td align="center" colspan="1" rowspan="1">6</td>
<td align="left" colspan="1" rowspan="1">C</td>
<td align="left" colspan="1" rowspan="1">A</td>
<td align="left" colspan="1" rowspan="1">6.15E-07</td>
<td align="center" colspan="1" rowspan="1">-0.042</td>
<td align="center" colspan="1" rowspan="1">0.008</td>
<td align="center" colspan="1" rowspan="1">0.427</td>
<td align="center" colspan="1" rowspan="1">24.866</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">rs114977861</td>
<td align="center" colspan="1" rowspan="1">6</td>
<td align="left" colspan="1" rowspan="1">T</td>
<td align="left" colspan="1" rowspan="1">C</td>
<td align="left" colspan="1" rowspan="1">2.07E-10</td>
<td align="center" colspan="1" rowspan="1">0.694</td>
<td align="center" colspan="1" rowspan="1">0.109</td>
<td align="center" colspan="1" rowspan="1">0.013</td>
<td align="center" colspan="1" rowspan="1">40.399</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">rs11754911</td>
<td align="center" colspan="1" rowspan="1">6</td>
<td align="left" colspan="1" rowspan="1">A</td>
<td align="left" colspan="1" rowspan="1">C</td>
<td align="left" colspan="1" rowspan="1">1.43E-06</td>
<td align="center" colspan="1" rowspan="1">0.095</td>
<td align="center" colspan="1" rowspan="1">0.020</td>
<td align="center" colspan="1" rowspan="1">0.049</td>
<td align="center" colspan="1" rowspan="1">23.237</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">rs148605442</td>
<td align="center" colspan="1" rowspan="1">6</td>
<td align="left" colspan="1" rowspan="1">G</td>
<td align="left" colspan="1" rowspan="1">A</td>
<td align="left" colspan="1" rowspan="1">8.01E-06</td>
<td align="center" colspan="1" rowspan="1">0.128</td>
<td align="center" colspan="1" rowspan="1">0.029</td>
<td align="center" colspan="1" rowspan="1">0.025</td>
<td align="center" colspan="1" rowspan="1">19.934</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">rs1929899</td>
<td align="center" colspan="1" rowspan="1">6</td>
<td align="left" colspan="1" rowspan="1">G</td>
<td align="left" colspan="1" rowspan="1">A</td>
<td align="left" colspan="1" rowspan="1">1.57E-06</td>
<td align="center" colspan="1" rowspan="1">0.054</td>
<td align="center" colspan="1" rowspan="1">0.011</td>
<td align="center" colspan="1" rowspan="1">0.163</td>
<td align="center" colspan="1" rowspan="1">23.062</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">rs4714209</td>
<td align="center" colspan="1" rowspan="1">6</td>
<td align="left" colspan="1" rowspan="1">C</td>
<td align="left" colspan="1" rowspan="1">T</td>
<td align="left" colspan="1" rowspan="1">4.18E-13</td>
<td align="center" colspan="1" rowspan="1">0.069</td>
<td align="center" colspan="1" rowspan="1">0.009</td>
<td align="center" colspan="1" rowspan="1">0.253</td>
<td align="center" colspan="1" rowspan="1">52.560</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">rs75516857</td>
<td align="center" colspan="1" rowspan="1">6</td>
<td align="left" colspan="1" rowspan="1">G</td>
<td align="left" colspan="1" rowspan="1">A</td>
<td align="left" colspan="1" rowspan="1">9.89E-06</td>
<td align="center" colspan="1" rowspan="1">0.108</td>
<td align="center" colspan="1" rowspan="1">0.025</td>
<td align="center" colspan="1" rowspan="1">0.035</td>
<td align="center" colspan="1" rowspan="1">19.534</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">rs9283907</td>
<td align="center" colspan="1" rowspan="1">6</td>
<td align="left" colspan="1" rowspan="1">A</td>
<td align="left" colspan="1" rowspan="1">G</td>
<td align="left" colspan="1" rowspan="1">1.52E-18</td>
<td align="center" colspan="1" rowspan="1">0.101</td>
<td align="center" colspan="1" rowspan="1">0.012</td>
<td align="center" colspan="1" rowspan="1">0.151</td>
<td align="center" colspan="1" rowspan="1">77.232</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/Tab1/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p"><div class="fn" id="_fn_p28"><p>SNP: single nucleotide polymorphism (instrumental variable); CHR: chromosomal location; EA indicates effector allele; OA indicates other allele; P: <em>P</em> value (Significance threshold); Beta: β value; Se: standard error; MAF: minor allele frequency; F: F statistic (Beta<sup>2</sup>/Se<sup>2</sup>)</p></div></div></section></section><section id="Sec15"><h3 class="pmc_sec_title">Positive control results</h3>
<p id="Par24">Positive control results (Supplementary Fig. <a href="#MOESM8" class="usa-link">1</a>) showed that GLP-1RA significantly reduced HbA1c levels (IVW method: OR = 0.95, 95%CI: 0.92–0.98, <em>P</em> = 0.0013), and both Weighted median method (OR = 0.96, 95%CI: 0.93-1, <em>P</em> = 0.0404) and simple mode method (OR = 0.92, 95%CI: 0.86–0.99, <em>P</em> = 0.0486) showed indicative proof of association. In addition, sensitivity analyses indicated that no significant heterogeneity or horizontal pleiotropy was found, suggesting a relatively reliable result.</p>
<p id="Par25">When we performed a positive control with T2D using the nine tool variables screened, the MR-PRESSO Outlier test found that ‘rs114977861’ and ‘rs1929899’ were outlier instrumental variables (Supplementary Table <a href="#MOESM4" class="usa-link">4</a>), so we excluded them. MR analysis was conducted using the remaining SNPs with T2D. IVW method revealed that GLP-1RA significantly decreased the incidence risk of T2D (OR = 0.84, 95%CI: 0.74–0.96, <em>P</em> = 0.0082), and Weighted median method also exhibited a similar result (OR = 0.83, 95%CI: 0.73–0.94, <em>P</em> = 0.0028). The above results further determined the effectiveness and reliability of the selected SNPs.</p></section><section id="Sec16"><h3 class="pmc_sec_title">MR insights into the causal relationship between GLP-1RA and DR</h3>
<p id="Par26">As shown in Fig. <a href="#Fig3" class="usa-link">3</a>A, in the MR results of the discovery cohort (GWAS catalog), increased expression of GLP-1R in blood tissues corresponded to a significantly lower risk of developing DR (IVW: OR = 0.47, 95%CI: 0.31–0.70, <em>P</em> = 0.0003), and the heterogeneity test results of the IVW method (<em>P</em> = 0.3196) and the MR-Egger regression method (<em>P</em> = 0.6167) indicated that heterogeneity was not significant and could be ignored. The MR-Egger intercept method (<em>P</em> = 0.0882) and the MR-PRESSO Global test method (<em>P</em> = 0.325) both demonstrated that there was no horizontal pleiotropic effect on the causal association of the genetic proxy GLP-1RA with DR, suggesting that the tool variable was not significantly influencing the outcome through pathways other than exposure. Meanwhile, the MR-PRESSO Outlier test method did not find outlier instrumental variables (no data were generated), indicating that the tool variables were overall robust, and the leave-one-out results also found no notable outlier SNPs (Supplementary Fig. <a href="#MOESM8" class="usa-link">2</a>A), which together with the above results of the sensitivity analyses, suggests that our MR results are relatively reliable.</p>
<figure class="fig xbox font-sm" id="Fig3"><h4 class="obj_head">Fig. 3.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12366118_13098_2025_1878_Fig3_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8591/12366118/aef0f7b603b1/13098_2025_1878_Fig3_HTML.jpg" loading="lazy" id="d33e826" height="278" width="669" alt="Fig. 3"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig3/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Main analysis results of the MR method. (<strong>A</strong>) Forest plot of the six analysis methods. Since the MR-PRESSO Outlier test method did not detect SNPs with potentially large bias in the two cohorts, no quantitative result messages about the MR-PRESSO Outlier test method were generated by the R software, so we did not present them in the figure. (<strong>B</strong>) Meta-analysis of the outcome of the MR method for the discovery cohort and the validation cohort</p></figcaption></figure><p id="Par27">Similarly, the results of the validation cohort (FinnGen) likewise supported these findings (IVW: OR = 0.71, 95%CI: 0.52–0.96, <em>P</em> = 0.0246). Moreover, the heterogeneity test and the horizontal pleiotropy test also indicated the absence of significant heterogeneity (IVW: <em>P</em> = 0.9921; MR-Egger: <em>P</em> = 0.9815) and horizontal pleiotropy (MR-Egger: <em>P</em> = 0.9151; MR-PRESSO Global test: <em>P</em> = 0.996). Similarly, the results of the MR-PRESSO Outlier test method and the leave-one-out method did not reveal significant outlier SNPs (Supplementary Fig. <a href="#MOESM8" class="usa-link">2</a>B). Meanwhile, Fig. <a href="#Fig3" class="usa-link">3</a> demonstrates that in the discovery cohort (GWAS-Catalog), the BWMR analysis revealed a statistically significant inverse association between GLP-1R gene expression and the risk of DR development (OR = 0.39, 95% CI: 0.24–0.62, <em>P</em> = 0.0001). Consistent with these findings, the BWMR analysis in the validation cohort (FinnGen Consortium) showed suggestive evidence of a protective effect of elevated GLP-1R gene expression against DR risk (OR = 0.70, 95% CI: 0.51–0.96, <em>P</em> = 0.029). These findings provide robust supplementary evidence and independent validation for the MR-IVW analysis.</p>
<p id="Par28">The findings of the meta-analysis illustrated in Fig. <a href="#Fig3" class="usa-link">3</a>B indicated that, although the <em>P</em>-value exceeded 0.1 and the I<sup>2</sup> statistic was greater than 50%, the presence of heterogeneity could not be disregarded [<a href="#CR22" class="usa-link" aria-describedby="CR22">22</a>, <a href="#CR23" class="usa-link" aria-describedby="CR23">23</a>]. The random effect model was used to quantitatively synthesize the main MR results (IVW method) of the discovery cohort and the validation cohort. The total effect is nevertheless meaningful (OR = 0.59,95% CI: 0.39–0.89, <em>P</em> = 0.0109), indicating that there is a significant causal association between GLP-1RA and DR risk reduction in the European population. In addition, we calculated the PPs of the five hypotheses by Bayesian co-localisation analysis and used PP.H4/(PP.H3 + PP.H4) &gt; 0.7 as evidence that the two traits, exposure and outcome, shared the same genetic variants [<a href="#CR24" class="usa-link" aria-describedby="CR24">24</a>–<a href="#CR26" class="usa-link" aria-describedby="CR26">26</a>]. It is not difficult to find that the co-localisation results of both cohorts suggest that exposure and outcome share the same genetic variants (Table <a href="#Tab2" class="usa-link">2</a>), further proving that our conclusions are relatively reliable.</p>
<section class="tw xbox font-sm" id="Tab2"><h4 class="obj_head">Table 2.</h4>
<div class="caption p"><p>Co-localisation analysis results for the discovery and validation cohorts</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<thead><tr>
<th align="left" colspan="1" rowspan="1">Cohort</th>
<th align="left" colspan="1" rowspan="1">PP.H0</th>
<th align="left" colspan="1" rowspan="1">PP.H1</th>
<th align="left" colspan="1" rowspan="1">PP.H2</th>
<th align="left" colspan="1" rowspan="1">PP.H3</th>
<th align="left" colspan="1" rowspan="1">PP.H4</th>
<th align="left" colspan="1" rowspan="1">PP.H4/(PP.H4 + PP.H3)</th>
</tr></thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1">GWAS-catalog</td>
<td align="left" colspan="1" rowspan="1">1.55E-12</td>
<td align="left" colspan="1" rowspan="1">5.67E-01</td>
<td align="left" colspan="1" rowspan="1">2.81E-13</td>
<td align="left" colspan="1" rowspan="1">1.03E-01</td>
<td align="left" colspan="1" rowspan="1">3.31E-01</td>
<td align="center" colspan="1" rowspan="1">0.7627</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">FinnGen</td>
<td align="left" colspan="1" rowspan="1">2.60E-12</td>
<td align="left" colspan="1" rowspan="1">9.54E-01</td>
<td align="left" colspan="1" rowspan="1">9.71E-15</td>
<td align="left" colspan="1" rowspan="1">3.52E-03</td>
<td align="left" colspan="1" rowspan="1">4.21E-02</td>
<td align="center" colspan="1" rowspan="1">0.9228</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/Tab2/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p"><div class="fn" id="_fn_p38"><p>PP: posterior probability; H0-H4: four co-location analysis hypotheses</p></div></div></section></section><section id="Sec17"><h3 class="pmc_sec_title">SMR insights into the causal relationship between GLP-1RA and DR</h3>
<p id="Par31">In the SMR analysis between blood GLP-1R target gene expression and DR risk, we visualised the SNP distribution and <em>P</em>-value relationship between the eQTL dataset and the GWAS dataset for DR, where the labelled dots are the instrumental variable top-SNPs (usually those with the smallest <em>P</em>-value in the exposure dataset), and the red line represents <em>P</em> = 0.025, above which indicates significant statistical significance, while the opposite does not suggest a significant cause-and-effect relation between exposure and outcome (Fig. <a href="#Fig4" class="usa-link">4</a>A, B). It was easy to find that the results from the discovery cohort showed evidence of a significant association (OR = 0.24, 95%CI: 0.08–0.74, <em>P</em> = 0.013), whereas the results from the validation cohort, although suggestive of an association between GLP-1R expression and a low risk of developing DR, were not statistically relevant (OR = 0.61, 95%CI: 0.32–1.21, <em>P</em> = 0.161), a result that could be attributed to underlying differences in individual samples. Therefore, in order to reduce the possible confounding bias while observing the total effect of the SMR method in the two datasets, we conducted Meta-analysis of the above two results. Since I<sup>2</sup> &lt; 50% and <em>P</em> &gt; 0.1 satisfy the conditions for the use of the fixed-effects model [<a href="#CR22" class="usa-link" aria-describedby="CR22">22</a>, <a href="#CR23" class="usa-link" aria-describedby="CR23">23</a>], we used the fixed-effects model to synthesise the two results. The total effect suggested a remarkable correlation between GLP-1R target gene expression and DR risk reduction (OR = 0.48, 95%CI: 0.27–0.86, <em>P</em> = 0.0129) (Fig. <a href="#Fig4" class="usa-link">4</a>C).</p>
<figure class="fig xbox font-sm" id="Fig4"><h4 class="obj_head">Fig. 4.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12366118_13098_2025_1878_Fig4_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8591/12366118/cedf5e4f2072/13098_2025_1878_Fig4_HTML.jpg" loading="lazy" id="d33e982" height="407" width="669" alt="Fig. 4"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig4/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Main analysis results of the SMR method. (<strong>A</strong>, <strong>B</strong>) Visualisation of the <em>P</em>-values of all available SNPs (grey dots) for DR in the GWAS catalog database and FinnGen database with the <em>P</em>-values of all SNPs (red or blue graphs below) in the eQTL data and the <em>P</em>-values of the SMR method (diamonds), where top-SNP points above the threshold line (red dashed line) represent the presence of a significant association. (<strong>C</strong>) Meta-analysis of the results of the two SMR methods. (<strong>D</strong>, <strong>E</strong>) Relative effects of SNPs used for the HEIDI test versus SNPs from the eQTL data. The orange dotted line represents the estimation of the SMR correlation effect size for top-SNPs</p></figcaption></figure><p id="Par32">In addition, the HEIDI test showed no remarkable heterogeneity or pleiotropy that would cause the results to be unreliable in the SMR analyses of the two DR endpoints (GWAS catalog: <em>P</em> = 0.3827; FinnGen: <em>P</em> = 0.9305). Figure <a href="#Fig4" class="usa-link">4</a>D, E illustrates the SNP effect sizes of the SNPs used in the HEIDI test (from GWAS catalog or FinnGen) relative to the SNP effect sizes from the eQTL data, and the closer these SNP distributions are to the orange dashed line represents a more precise HEIDI test result. We provide more information on the SMR analyses in Supplementary Table <a href="#MOESM5" class="usa-link">5</a>.</p></section><section id="Sec18"><h3 class="pmc_sec_title">Insights from systematic reviews of clinical cohort studies</h3>
<p id="Par34">From the three databases, we retrieved a total of 1,508 relevant publications, including Pubmed (149), Embase (1,281) and Cochrane library (78), and the remaining 1,265 articles were included in the primary screening by removing duplicates of published articles. By reviewing the article titles and abstracts, 115 studies were selected for rescreening, resulting in 3 studies for inclusion in the review. The fundamental characteristics and quality assessment outcomes of the studies are presented in Supplementary Table <a href="#MOESM6" class="usa-link">6</a>. Given the restricted number of studies included and the lack of uniformity in the interventions across these studies, this research employed qualitative analysis to investigate the relationship between GLP-1RA and the risk of developing DR in real-world settings.</p>
<p id="Par35">The primary results of the three cohort studies are presented and summarised in Table <a href="#Tab3" class="usa-link">3</a>. Overall, a total of two studies reported a clear negative association between GLP-1RA and DR [<a href="#CR27" class="usa-link" aria-describedby="CR27">27</a>, <a href="#CR28" class="usa-link" aria-describedby="CR28">28</a>]. Among them, Zheng et al. pooled T2D patients from several national registries in Sweden and applied COX regression models to explore the association between GLP-1RA and DR using liraglutide, dulaglutide, and semaglutide as exposures, and metformin and sulfonylurea as controls. After adjusting for confounding factors such as age and educational level at the time of diabetes diagnosis, it was found that the risk of DR incidence in the exposed group was significantly lower than that in the control group (HR = 0.44, 95% CI: 0.3–0.64), and this association remained statistically significant after controlling for diabetes duration, hypertension, cardiovascular events, and the doses of metformin and sulfonylurea drugs (<em>P</em> &lt; 0.0001). In subgroup analyses, similar results were observed in men (HR = 0.34, 95% CI: 0.21–0.55), but no statistically significant evidence was found in women (<em>P</em> = 0.0829). Interestingly, this article also analysed the correlation between pancreatic tissue GLP-1R expression and DR risk using the SMR approach and found that the correlation remained significant in background DR versus severe non-proliferative DR. However, the article did not provide detailed information on HbA1c and blood glucose control, which makes it difficult to investigate the impact of GLP-1 RA on blood glucose control and HbA1c in European DR patients, as well as the influence of blood glucose on the results. Antonios Douros adopted a time-varying exposure definition to align with the dynamic nature of drug therapy for type 2 diabetes, using a COX hazard ratio model to conduct a cohort study of T2D patients from the UK Clinical Practice Centre. Exenatide, liraglutide, and lixisenatide were used as single agents or in combination with non-insulin antidiabetic drugs as exposures, with insulin as the control. The study found that the overall risk of DR was reduced with GLP-1RA (HR = 0.67, 95% CI: 0.51–0.9). In subgroup analyses by duration of drug exposure, a significant reduction in the risk of DR was found after one year of drug use, yet, the risk was similar in the exposed and control groups when the duration of drug use was less than 6 months and 6.1–12 months. The study also reported no significant association between GLP-1RA and overall DR incidence compared to two or more currently used oral hypoglycaemic agents, although HR &lt; 1 was found for both duration of use less than 6 months and use longer than 12 months, but still without statistically significant. Moreover, Jakob Hasselstrøm Jensen et al. [<a href="#CR29" class="usa-link" aria-describedby="CR29">29</a>], based on a Danish population-based study, found that using metformin combined with a dipeptidyl peptidase 4 inhibitor (DPP-4I) as a baseline control, this treatment regimen was observed to be associated with an increased risk of DR in the group of GLP-1RA (Exenatide, Liraglutide, Lixisenatide, Dulaglutide) combined with metformin, but relative to the metformin combined with insulin group, this regimen had a lower risk of DR but still higher than that of the metformin combined with DPP-4I group and the sodium-glucose cotransporter protein-2 inhibitor (SGLT-2I) group. Unlike other large-scale real-world studies such as SUSTAIN-6, LEADER, and REWIND [<a href="#CR30" class="usa-link" aria-describedby="CR30">30</a>], which treat DR as a secondary outcome rather than a primary outcome, these three studies directly set DR occurrence as the outcome while conducting retrospective analyses using large-scale cohort studies, thereby enabling a more precise assessment of the relationship between GLP-1RAs and DR. However, these studies also have certain limitations, such as data primarily sourced from registration centres, which may include data errors. Additionally, the interventions in these studies included various GLP-1RAs and other antidiabetic medications, and the controls were selected from currently first- or second-line antidiabetic medications rather than placebos. Therefore, the possibility of drug interactions interfering with the results cannot be ruled out. Compared with other antidiabetic medications, these studies can only indicate whether the effects are superior or inferior to those medications, and cannot directly reveal whether GLP-1RAs can reduce the risk of DR onset. Furthermore, the duration of diabetes in the patients included in these studies was relatively short. An observational study [<a href="#CR31" class="usa-link" aria-describedby="CR31">31</a>] spanning 28 years and involving 4,513 patients with type 2 diabetes revealed that the incidence of DR significantly increased with the duration of diabetes. The incidence of DR in the early stages (0–5 years) was 6.6%, and by 10–15 years, this proportion increased to 24.0%. Therefore, if the duration of diabetes and the follow-up observation period of the included study subjects are insufficient, it may be difficult to determine whether the absence of DR during the observation period is due to the protective effect of the drug or individual factors, potentially leading to false-positive or false-negative results. Collectively, these results indicate that for individuals with T2D, GLP-1RA may be safer and offer potential benefits for retinal progression in these patients compared to traditional glucose-lowering agents such as insulin; however, additional large cohort studies focusing on European populations are necessary to substantiate this perspective.</p>
<section class="tw xbox font-sm" id="Tab3"><h4 class="obj_head">Table 3.</h4>
<div class="caption p"><p>Main results of three cohort studies based on European populations</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" rowspan="2" colspan="1">Study</th>
<th align="left" colspan="2" rowspan="1">Exposure group</th>
<th align="left" colspan="2" rowspan="1">Control group</th>
</tr>
<tr>
<th align="left" colspan="1" rowspan="1">Events</th>
<th align="left" colspan="1" rowspan="1">Nonevents</th>
<th align="left" colspan="1" rowspan="1">Events</th>
<th align="left" colspan="1" rowspan="1">Nonevents</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1">Deqiang Zheng 2023 [<a href="#CR26" class="usa-link" aria-describedby="CR26">26</a>]</td>
<td align="center" colspan="1" rowspan="1">31</td>
<td align="center" colspan="1" rowspan="1">2,359</td>
<td align="center" colspan="1" rowspan="1">398</td>
<td align="center" colspan="1" rowspan="1">11,331</td>
</tr>
<tr>
<td align="left" rowspan="2" colspan="1">Antonios Douros 2018* [<a href="#CR27" class="usa-link" aria-describedby="CR27">27</a>]</td>
<td align="center" colspan="1" rowspan="1">173</td>
<td align="center" colspan="1" rowspan="1">271</td>
<td align="center" colspan="1" rowspan="1">2,386</td>
<td align="center" colspan="1" rowspan="1">8,045</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1">98</td>
<td align="center" colspan="1" rowspan="1">2,508</td>
<td align="center" colspan="1" rowspan="1">226</td>
<td align="center" colspan="1" rowspan="1">5,330</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Jakob Hasselstrøm Jensen 2024 [<a href="#CR28" class="usa-link" aria-describedby="CR28">28</a>]</td>
<td align="center" colspan="1" rowspan="1">84</td>
<td align="center" colspan="1" rowspan="1">3,946</td>
<td align="center" colspan="1" rowspan="1">106</td>
<td align="center" colspan="1" rowspan="1">8,847</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/Tab3/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p"><div class="fn" id="_fn_p47"><p>*The article contains two cohorts: the first row represents GLP-1RA with two and more glucose-lowering drugs (without insulin); the second row represents GLP-1RA with insulin</p></div></div></section></section></section><section id="Sec19"><h2 class="pmc_sec_title">Discussion</h2>
<p id="Par37">Diabetes mellitus, as one of the most common chronic endocrine diseases, not only influences the normal life of nearly 508 million people around the world, but also has a significant effect on social and economic development [<a href="#CR32" class="usa-link" aria-describedby="CR32">32</a>]. Although the guidelines and treatments for diabetes management are continuously renewed, the more serious problem is that diabetic patients are also at an increasing risk of developing chronic complications such as nephropathy, neuropathy and retinopathy [<a href="#CR33" class="usa-link" aria-describedby="CR33">33</a>]. Among them, DR, as a major ocular complication in diabetic patients, has a poor prognosis and remains a global health concern. However, thanks to the popularity of optical coherence tomography (OCT) imaging and the refinement of anti-vascular endothelial growth factor (VEGF) therapeutic strategies over the past decades, landmark advances for the prevention and management of DR have been achieved [<a href="#CR34" class="usa-link" aria-describedby="CR34">34</a>]. However, in recent years, with the use of novel glucose-lowering drugs such as GLP-1RA [<a href="#CR35" class="usa-link" aria-describedby="CR35">35</a>], which have been a boon for diabetic patients, it is necessary to examine whether these novel drugs carry a risk of inducing DR. Therefore, from a genetically inherited perspective, we used MR and SMR methods, supported by the huge data from public databases, to dig deeper into the association between GLP-1R gene expression in blood tissues (mimicking the effect of GLP-1RA) and the risk of DR in European populations. At the same time, we also attempted to comprehensively search for real-world cohort studies set in European populations and summarise these studies’ perspectives on the relationship between GLP-1RA and the risk of developing DR. We found that both the discovery cohort and the validation cohort showed a remarkable negative association between GLP-1R gene expression and the risk of DR in the primary analysis using the MR method, and these results were in agreement with the Meta-analysis results. In the analysis of SMR method, the results of the discovery cohort were similar to those of MR, while the results of the validation cohort were not statistically significant but still suggested a potential negative correlation between the two, and the results of the Meta-analysis still indicated that GLP-1R gene expression in blood tissues was significantly associated with a reduced risk of DR. Taken together, the results of these analyses suggest that GLP-1RA decreases the risk of DR. Among the three clinical cohort trial publications we searched, two studies reported that the prognosis of T2D patients with GLP-1RA was remarkably superior to that of currently used hypoglycaemic agents, and the other study reported that GLP-1RA increased the risk of DR in T2D patients, but the existence of other confounding factors on the results of the above studies cannot be excluded. Therefore, these findings need to be validated in multicentre randomised controlled trials and cohort studies with longer follow-up periods and including more participants of European origin.</p>
<p id="Par38">In summary, our study reveals that GLP-1RAs have been proven to have a protective effect against DR in European populations at the genetic level, but their reliability and universality in clinical practice still need to be further verified. Currently, diabetic patients mainly control their blood glucose levels through lifestyle interventions, diabetes self-management education and support, and dependence on insulin or oral hypoglycaemic agents (such as metformin, pioglitazone, etc.) [<a href="#CR36" class="usa-link" aria-describedby="CR36">36</a>, <a href="#CR37" class="usa-link" aria-describedby="CR37">37</a>]. Given the cardiovascular protective effects of GLP-1RAs, the 2025 American Diabetes Association (ADA) guidelines recommend them as the first-line medication for blood glucose management in patients with T2D and advanced chronic kidney disease (CKD) [<a href="#CR38" class="usa-link" aria-describedby="CR38">38</a>]. However, as a chronic complication of diabetes, DR often lacks obvious symptoms in its early stages, making timely diagnosis and treatment challenging. Additionally, GLP-1RAs can protect the retina by inhibiting endothelial cell dysfunction (ECD), a mechanism that is particularly important in the early stages of diabetic vascular complications. Therefore, for diabetic patients, especially those with early signs of retinopathy, GLP-1RAs may be considered as part of a comprehensive treatment plan with long-term follow-up. Previous clinical trials have confirmed that GLP-1RAs have certain protective effects on the cardiovascular system, microvasculature, and kidneys [<a href="#CR39" class="usa-link" aria-describedby="CR39">39</a>]. Additionally, some studies have found that GLP-1RAs can reduce intraocular pressure and the risk of glaucoma [<a href="#CR40" class="usa-link" aria-describedby="CR40">40</a>]. These findings are particularly important for diabetic patients at high risk of DR, macrovascular disease, or kidney disease, suggesting that GLP-1RAs may help prevent or mitigate the combined effects of multiple complications, thereby improving patients’ quality of life. Furthermore, for overweight or obese T2DM patients, GLP-1RAs with weight-loss effects are recommended for monotherapy or combination therapy [<a href="#CR38" class="usa-link" aria-describedby="CR38">38</a>].</p>
<p id="Par39">Personalised treatment is particularly critical when developing treatment plans. Based on the results of this study and in conjunction with the patient’s genetic background, clinicians can assess whether the patient is suitable for adding GLP-1RAs to their existing hypoglycaemic regimen to leverage their potential protective effects on retinopathy. In this study, we selected nine SNPs with high association strength with the GLP-1R gene as strong instrumental variables. For European DR patients carrying these genetic variants, GLP-1RAs may be prioritised, with close monitoring of their efficacy in improving retinopathy. For patients without these genetic variants, alternative treatment combinations may need to be explored; however, these inferences require further validation through clinical trials. Regarding drug dosage, the maximum clinical trial dose of GLP-1RAs (such as liraglutide) reported in T1D is 1.8 mg/day subcutaneous injection [<a href="#CR6" class="usa-link" aria-describedby="CR6">6</a>], which can to some extent mitigate the impact of severe gastrointestinal reactions on tolerability and treatment adherence. Clinically, the recommended starting dose for liraglutide is 0.6 mg/day, which can be increased to 1.2 mg/day after one week based on clinical response. The recommended initial dose for semaglutide is 0.25 mg/day, which is increased to 0.5 mg after four weeks, followed by another four weeks, until the maintenance dose (0.5 mg or 1.0 mg) is reached [<a href="#CR39" class="usa-link" aria-describedby="CR39">39</a>]. Currently, the primary side effects of GLP-1 RAs are widely recognised as gastrointestinal reactions, such as nausea, vomiting, and diarrhoea, but the risk of hypoglycaemia is low. It is important to note that when used in combination with diabetes medications known to cause hypoglycaemia (such as insulin or glinides), hypoglycaemic events may occur. Therefore, when using these medications in combination, it is essential to monitor the patient’s tolerance and blood glucose levels and adjust the dosage appropriately [<a href="#CR41" class="usa-link" aria-describedby="CR41">41</a>]. In summary, when developing a hypoglycaemic treatment plan, it is recommended that patients participate in the decision-making process with their healthcare team, taking into account the hypoglycaemic efficacy, potential side effects, availability, and economic burden of the drugs. Additionally, regardless of the circumstances, the effectiveness, safety, risk of hypoglycaemia, and overall treatment status of the patient should be continuously assessed [<a href="#CR42" class="usa-link" aria-describedby="CR42">42</a>].</p>
<p id="Par40">Given the complex heterogeneity of obesity and diabetes, traditional single-drug or single-target treatment strategies often fail to achieve optimal efficacy. To overcome this limitation, integrating multiple metabolic pathways into a single treatment regimen may enhance therapeutic efficacy through synergistic effects of multiple mechanisms. However, the multi-drug combination regimen faces numerous challenges in drug development and clinical research, with relatively cumbersome processes. Given this, developing single-molecule multi-receptor agonists that can simultaneously act on multiple receptors with balanced activity has emerged as a more promising alternative. Compared to using single agonists separately, single-molecule multi-receptor agonists can simultaneously activate multiple signalling pathways, not only maximising therapeutic effects but also reducing side effects and optimising pharmacokinetic properties. Currently, GLP-1-based single-molecule multi-receptor agonists have evolved into five main types, including GLP-1/gastric inhibitory polypeptide (GIP) receptor agonists, GLP-1/glucagon (GCG) receptor agonists, GLP-1/GIP/GCG receptor agonists, GLP-1/GCG/FGF21 (human fibroblast growth factor 21) triple agonists, and GLP-1/GIP/IGF-1 (insulin-like growth factor 1)/GCG receptor agonists. The emergence of these novel agonists not only opens new avenues for the treatment of obesity and diabetes but also provides clear directional guidance for future drug development, preclinical, and clinical research [<a href="#CR43" class="usa-link" aria-describedby="CR43">43</a>–<a href="#CR45" class="usa-link" aria-describedby="CR45">45</a>].</p>
<p id="Par41">In addition, the pathogenesis of DR is complex, involving factors such as retinal microvascular damage induced by hyperglycemia, vascular endothelial dysfunction, inflammatory responses, and oxidative stress. These factors are intricately intertwined, forming a complex pathological cascade. Therefore, actively seeking strategies to improve microvascular damage, protect vascular endothelial cell function, and reduce inflammation and oxidative stress are important treatment approaches for DR patients [<a href="#CR46" class="usa-link" aria-describedby="CR46">46</a>, <a href="#CR47" class="usa-link" aria-describedby="CR47">47</a>]. Currently, most studies report that GLP−1RAs can reduce the risk of disease progression in DR patients and exert retinal vascular and neuroprotective effects through the aforementioned mechanisms. He’s team treated diabetic mice (db/db) with GLP−1RAs (Loxenatide and Semaglutide, et al.) and found that while increasing retinal vascular density and branching index in mice, the length and extension area of blood vessels were also improved. Additionally, GLP−1RAs maintain mitochondrial integrity and regulate redox balance in retinal endothelial cells, thereby inhibiting high blood glucose-induced mitochondrial DNA leakage and STING pathway activation. They also downregulate VCAM−1, IL−1β, and VEGF expression while upregulating VE-cadherin and ZO−1 expression levels, thereby reducing inflammatory responses and endothelial cell death [<a href="#CR48" class="usa-link" aria-describedby="CR48">48</a>]. Puddu et al. [<a href="#CR49" class="usa-link" aria-describedby="CR49">49</a>] further noted that GLP−1R is widely expressed in retinal endothelial cells, and its activation significantly inhibits the expression and secretion of multiple inflammatory factors such as TNF-α and IL−1α, reducing immune cell infiltration. Chen’s research found that GLP−1R and SGLT2 expression was significantly downregulated in DR patients and negatively correlated with high expression levels of pro-inflammatory cytokines such as tumour necrosis factor (TNF-α) and interferon (IFN-γ). This suggests that GLP−1RAs may restore the expression of GLP−1R to re-establish the regulatory capacity of retinal cells against inflammatory signals, thereby improving vascular abnormalities and inflammatory states in the progression of DR [<a href="#CR50" class="usa-link" aria-describedby="CR50">50</a>]. These results indicate that GLP−1RAs play a central regulatory role in alleviating diabetes-related immune inflammatory responses. Additionally, GLP−1RAs can enhance endothelial nitric oxide synthase (eNOS) activity and NO production by activating the PI3K/Akt and AMPK-eNOS pathways, thereby improving endothelial-dependent vasodilation in diabetic mice and reducing endothelial inflammation and vascular constriction. GLP−1RAs may also exert anti-inflammatory effects by reducing the production of advanced glycation end products (AGEs) and inhibiting the activation of the NF-κB pathway, thereby effectively preventing the onset and progression of early endothelial dysfunction in diabetic patients [<a href="#CR51" class="usa-link" aria-describedby="CR51">51</a>]. Further studies have reported that GLP−1RAs suppress inflammatory responses by activating GLP−1R in central neurons and regulating the ‘GLP−1-brain-immune axis.’ This activation pathway can attenuate the induction of plasma TNF-α by various Toll-like receptor (TLR) agonists, ultimately achieving an anti-inflammatory effect. Notably, this mechanism does not rely on the hypothalamic-pituitary-adrenal axis (HPA axis) or lipid-mediated inflammatory regulation but instead regulates inflammatory factor expression through neuroendocrine pathways mediated by activation of α1-adrenergic receptors and δ and κ-opioid receptors, thereby exerting an immunosuppressive effect [<a href="#CR52" class="usa-link" aria-describedby="CR52">52</a>].</p>
<p id="Par42">The protective effect of GLP−1RAs in diabetic retinopathy is also closely related to their inhibition of oxidative stress [<a href="#CR53" class="usa-link" aria-describedby="CR53">53</a>]. Zeng’s research found that when the GLP−1 analog Exendin−4 was administered early in the treatment of streptozotocin (STZ)-induced diabetic rats, the mRNA expression levels of Sirt1 and Sirt3 in the diabetic group decreased by 67% and 51%, respectively, compared to the control group. However, in the diabetic group treated with Exendin−4, the protein expression levels of Sirt1 and Sirt3 increased by 3-fold and 2-fold, respectively, compared to the diabetic group, suggesting that Exendin−4 enhances antioxidant capacity by upregulating NAD⁺-dependent Sirt1 and Sirt3 expression, significantly reducing Reactive Oxygen Species (ROS) levels and cell apoptosis in the early stages of diabetic rat retinas, and promoting the recovery of impaired visual function [<a href="#CR54" class="usa-link" aria-describedby="CR54">54</a>]. Further studies have found that hyperglycaemia can impair the antioxidant defence system by inhibiting Nrf2 activity, while GLP−1RA can reverse this change by activating the Nrf2 signalling pathway to enhance antioxidant gene expression, thereby promoting ROS clearance. This has been identified as a new target for the prevention and treatment of diabetic complications in multiple studies [<a href="#CR55" class="usa-link" aria-describedby="CR55">55</a>]. Another study found that downregulation of GLP−1R in retinal pigment epithelial (RPE) cells leads to increased intracellular ROS production, which activates the endoplasmic reticulum (ER) stress signalling pathway. ER stress further induces increased expression of p53 protein and Bax gene, ultimately leading to increased RPE cell apoptosis. Exendin−4 treatment can inhibit high glucose-induced ROS production, ER stress signalling pathway activation, and p53 expression [<a href="#CR56" class="usa-link" aria-describedby="CR56">56</a>]. Additionally, oxidative stress is an important factor in inducing retinal ganglion cell apoptosis and autophagy. Studies have shown that activation of the GLP−1 receptor downregulates the expression of NADPH oxidase NOX3 and mitochondrial superoxide dismutase SOD2, thereby reducing ROS levels, blocking the oxidative stress-induced upregulation of Beclin−1 expression and increased LC3-II/I ratio, and delaying autophagosome formation [<a href="#CR57" class="usa-link" aria-describedby="CR57">57</a>]. More importantly, GLP−1R negatively regulates autophagy activity through the ERK1/2-HDAC6 signalling pathway. In the retinas of diabetic rats, GLP−1 treatment significantly reduced the expression of phosphorylated ERK1/2 and its downstream HDAC6. HDAC6 is a key regulator of non-selective autophagy, and its enhanced activity promotes autophagosome formation by deacetylating substrates such as α-tubulin. By inhibiting this pathway, GLP−1R blocks HDAC6-induced autophagic overactivation, thereby alleviating Retinal ganglion cells (RGCs) damage and apoptosis [<a href="#CR57" class="usa-link" aria-describedby="CR57">57</a>]. Additionally, GLP−1R regulates mitochondrial autophagy by maintaining mitochondrial homeostasis. In an H₂O₂-induced RGC−5 cell damage model, liraglutide pretreatment not only reduced the expression of Beclin−1 and LC3-II/I but also upregulated PGC−1α to promote mitochondrial biogenesis while inhibiting mitochondrial autophagy pathways mediated by BNIP3L and Parkin. This process effectively improved mitochondrial dysfunction by maintaining mitochondrial membrane potential, reducing mitochondrial swelling, and inhibiting excessive ROS production, thereby alleviating RGCs apoptosis and axonal degeneration [<a href="#CR58" class="usa-link" aria-describedby="CR58">58</a>]. However, further investigation is needed to elucidate the specific regulatory relationships between GLP−1R agonists and different autophagy subtypes (e.g., selective mitochondrial autophagy, endoplasmic reticulum autophagy), and to clarify the differential roles of GLP−1R in different retinal cell types using technologies such as spatial transcriptomics at the single-cell level, to achieve precise intervention in DR treatment. In summary, these findings suggest that GLP−1R can reverse high blood sugar-induced retinal damage by alleviating microvascular and endothelial cell damage, improving mitochondrial function and homeostasis, and inhibiting the cascade reactions caused by inflammatory factors and ROS.</p>
<p id="Par43">Notably, increasing epidemiological and basic research evidence indicates that the pathogenesis of DR is not limited to microvascular lesions; functional impairments and degenerative changes in retinal neurons, particularly ganglion cell damage, are present in the early stages of the disease. This ‘neurovascular unit damage’ is considered a key pathological basis for early-stage DR [<a href="#CR59" class="usa-link" aria-describedby="CR59">59</a>, <a href="#CR60" class="usa-link" aria-describedby="CR60">60</a>]. Studies have shown that GLP−1R is expressed in the retina of humans and various diabetic animal models, providing a distribution basis for GLP−1RAs to directly act on retinal neurons [<a href="#CR61" class="usa-link" aria-describedby="CR61">61</a>, <a href="#CR62" class="usa-link" aria-describedby="CR62">62</a>]. Additionally, the neuroprotective effects of GLP−1RAs have been shown to be achieved through multiple mechanisms. On one hand, GLP−1RAs (such as Exendin−4) can effectively inhibit the expression and activity of L-type voltage-gated calcium channels (L-VGCCs) under hyperglycaemic conditions, thereby reducing calcium overload caused by excessive calcium influx, preventing the activation of downstream neuronal apoptosis pathways. By activating the GLP−1R-mediated Gs/cAMP/PKA/ryanodine/Ca<sup>2+</sup>/CaM/Calcineurin/PP1 signalling pathway, L-VGCCs are inactivated, significantly reducing RGCs loss without significantly affecting blood glucose levels, and enhancing discharge capacity under light stimulation, thereby achieving protection of RGCs [<a href="#CR63" class="usa-link" aria-describedby="CR63">63</a>]. On the other hand, GLP−1RAs can also prevent neuronal apoptosis caused by glutamate excitotoxicity by regulating glutamate homeostasis in the retina. In the db/db mouse model, local administration of GLP−1RAs reverses diabetes-induced downregulation of GLAST (glutamate-aspartate transporter), reduces extracellular glutamate accumulation, and activates anti-apoptotic signalling pathways such as Bcl−2 and AKT, thereby inhibiting the expression of apoptotic factors such as iNOS, FasL, and caspase−8 [<a href="#CR62" class="usa-link" aria-describedby="CR62">62</a>, <a href="#CR64" class="usa-link" aria-describedby="CR64">64</a>]. Additionally, some researchers have found that local administration of liraglutide via eye drops can effectively replenish reduced GLP−1 levels in the retina under diabetic conditions, activate the GLP−1R/Akt/GSK3β signalling pathway, reduce abnormal phosphorylation of tau protein at Ser396 and Thr231 sites, and alleviate synapse damage and mitochondrial dysfunction induced by these abnormalities, thereby exerting neuroprotective effects [<a href="#CR65" class="usa-link" aria-describedby="CR65">65</a>]. In addition to the above studies, another novel research focus is the improvement of functional impairments in early DR by GLP−1RAs through promoting the release of the inhibitory neurotransmitter GABA (gamma-aminobutyric acid). Studies have found that early-stage diabetes (4 weeks of hyperglycaemia) leads to a reduction in the frequency of GABAergic miniature inhibitory postsynaptic currents in RGCs, while GLP−1 eye drops can significantly increase this frequency, enhance RGCs survival rates, and improve visual function. This process is associated with the activation of the phospholipid-phospholipase C (PI-PLC)/inositol 1,4,5-trisphosphate receptor (IP3R)/Ca²⁺/protein kinase C (PKC) signalling pathway, which promotes GABA release from amacrine cells (ACs) to RGCs and inhibits excitotoxic processes associated with DR [<a href="#CR66" class="usa-link" aria-describedby="CR66">66</a>]. These findings suggest that GLP−1RAs may possess direct neuroprotective functions in the retina independent of their hypoglycaemic effects. Therefore, re-examining the pathogenesis of DR from the perspective of ‘early neuropathy’ provides new targets and theoretical basis for early intervention strategies in DR, and also highlights the potential and necessity of locally delivering GLP−1RAs for ophthalmic therapy.</p>
<p id="Par44">In recent years, the protective effects of GLP−1RAs on the blood-retinal barrier (BRB) have also garnered attention. Upon activation of the GLP−1R, inhibition of the RhoA/ROCK signalling pathway reduces the phosphorylation of myosin light chain (MLC), thereby maintaining the integrity of tight junction proteins such as Occludin and ZO−1, and protecting the BRB from hyperglycaemia-induced damage [<a href="#CR52" class="usa-link" aria-describedby="CR52">52</a>]. Additionally, GLP−1RAs significantly reduce the expression of MMP−9, VEGF, and ICAM−1 and inhibit the ERK1/2 and AKT/PKB signalling pathways, thereby alleviating inflammatory responses and vascular leakage, further protecting the BRB [<a href="#CR52" class="usa-link" aria-describedby="CR52">52</a>, <a href="#CR67" class="usa-link" aria-describedby="CR67">67</a>]. These mechanisms collectively not only maintain the integrity of the BRB but also improve retinal function in DR, highlighting the potential advantages of the BRB as a therapeutic target for DR patients.</p>
<p id="Par45">In real-world research, the findings from cohort studies conducted on European populations have been systematically reviewed in the relevant sections of this article. However, the global evidence regarding the association between GLP-1RAs and DR remains inconclusive. A study involving 47 patients reported that GLP-1RA treatment was associated with a transient worsening of DR in the short term, but longer-term follow-up demonstrated a partial improvement in DR risk with continued therapy [<a href="#CR68" class="usa-link" aria-describedby="CR68">68</a>]. In contrast, a retrospective cohort study of 1,626 individuals of Chinese descent revealed a significantly lower incidence of DR in the GLP-1RA group compared to those treated with insulin or oral hypoglycemic agents. This association persisted in both univariate and multivariate logistic regression analyses, even after adjusting for age and sex [<a href="#CR48" class="usa-link" aria-describedby="CR48">48</a>]. Conversely, other studies have suggested a potential increase in DR risk with GLP-1RA use. For instance, a retrospective cohort study utilizing data from the TriNetX global health research network, conducted by A. Eleftheriadou et al., compared DR risk in patients with type 2 diabetes receiving insulin therapy in combination with either SGLT-2Is or GLP-1RAs. The results indicated that patients treated with GLP-1RAs in combination with insulin exhibited a higher likelihood of developing DR compared to those receiving SGLT-2Is with insulin, a risk profile similar to that observed in the insulin-only control group [<a href="#CR69" class="usa-link" aria-describedby="CR69">69</a>]. However, this study was not a randomised controlled trial but an observational cohort study using electronic health record data from populations in the United States, Europe, and the Asia-Pacific region. While this study design is more conducive to temporal causal inference, it may introduce confounding factors such as regional and lifestyle differences, as well as selection bias, which could affect the reliability of the results. Additionally, both the SGLT-2I and GLP-1RA intervention groups and the control group used insulin, but the results of using GLP-1RA alone were not mentioned in the article. Therefore, it is unclear whether there is an interaction between insulin and GLP-1RA that affects the results. Similarly, a previous large-scale clinical trial (SUSTAIN-6) also indicated that the use of GLP-1RAs was associated with an increased risk of DR compared to the placebo group [<a href="#CR39" class="usa-link" aria-describedby="CR39">39</a>], but this result was based on 3,297 T2D patients from 20 countries, and 83.0% of the patients included in the trial already had cardiovascular disease or chronic kidney disease, indicating that the patient population had a high risk of complications. This high-risk population may respond differently to GLP-1RA than the general population, leading to an increased risk of DR. Furthermore, in the subgroup analysis, the authors only discussed the primary outcomes (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) and did not perform a subgroup analysis of the association between semaglutide, placebo, and DR. Therefore, the interference of regional and racial differences on the inference of risk associations cannot be ignored. Furthermore, differing definitions of DR may also account for variations in study results. This study defined vitreous haemorrhage, blindness, or the need for intravitreal medication or photocoagulation therapy as secondary endpoints. Since the primary objective of the trial was to assess cardiovascular safety, this may have led to an imprecise estimation of DR risk. Another large clinical trial by the same team (LEADER) reported similar results, with a higher incidence of retinal lesions in participants receiving subcutaneous liraglutide compared to the placebo group, though this difference was not statistically significant. This outcome may be attributed to the fact that most patients were using antihypertensive drugs, statins, and other medications, which could influence cardiovascular and microvascular complications and thereby affect the efficacy of GLP-1RA on DR. Similarly, this study also treated DR as a secondary endpoint, which may have limited the assessment of the association between GLP-1RA and DR. Another key point is that the median observation periods for these two trials (LEADER and SUSTAIN-6) were 3.8 years and 2.1 years, respectively, which are relatively short. For assessing the risk of chronic complications like DR, longer follow-up periods may be needed to observe the long-term effects of GLP-1RAs. Additionally, some studies have reported that an increased risk of DR is associated with a significant reduction in HbA1c levels within a short period of GLP-1RA use [<a href="#CR70" class="usa-link" aria-describedby="CR70">70</a>], suggesting that shorter follow-up periods may not adequately capture potential changes in DR risk associated with GLP-1RA. Therefore, larger-scale, longer-term follow-up, and more precise clinical trials are urgently needed to comprehensively examine the association between GLP-1RA and DR risk, particularly focusing on the use of first-line antidiabetic drugs (such as insulin) or the combination of multiple GLP-1RAs.</p></section><section id="Sec20"><h2 class="pmc_sec_title">Limitations</h2>
<p id="Par46">Although this study strictly followed the analytical procedures, it inevitably has certain limitations. Firstly, regarding data sources, since all data used in this paper are from publicly available databases, the data quality may be affected by the sample size of the original studies and the limitations of different statistical methods. Moreover, we chose blood tissue eQTLs rather than retinal tissue. Compared to blood tissue, retinal tissue has unique cell types and physiological functions, and its gene expression regulation may significantly differ from that of blood tissue [<a href="#CR71" class="usa-link" aria-describedby="CR71">71</a>]. Therefore, the instrumental variables selected based on blood eQTL data may not accurately reflect the true gene expression and functional roles in the retina. Additionally, gene expression in blood may be influenced by various confounding factors, such as inflammatory factors and metabolites, which may not exist or have different mechanisms in the retina, leading to potential biases in the results [<a href="#CR72" class="usa-link" aria-describedby="CR72">72</a>]. Secondly, our analysis was conducted based on a European population, so the generalizability of our findings to other ethnic groups remains debatable. Furthermore, the drug-targeted MR or SMR results reflect the long-term impact of blood tissue genetic proxies for GLP-1RA on DR, which may not align with the results of clinical trials conducted over relatively limited time periods. Lastly, our research focus was limited to the impact of GLP-1RA on the onset of DR, but we did not address whether the use of GLP-1RA in DR patients would exacerbate or alleviate disease progression. In terms of systematic literature review, only three studies were included. On the positive side, we selected these three studies because they focused on the European population and met other stringent criteria, indicating that they have high representativeness and reference value, which to some extent reduces bias and enhances the persuasiveness of our study. Additionally, through in-depth analysis of these studies, we gained a more detailed understanding of the use of GLP-1RA in the European diabetic population, providing direction and insights for subsequent broader research. However, on the negative side, the limited number of included studies also has certain limitations. These studies, all conducted in European populations, make it difficult to generalize the findings to broader populations and different regions. Moreover, potential differences in sample characteristics may lead to high heterogeneity in the results, making it challenging to synthesize them into a universally applicable conclusion. Future research should include more real-world studies to confirm our findings and pay greater attention to the potential role of GLP-1RA in treating DR patients and its impact on prognosis.</p></section><section id="Sec21"><h2 class="pmc_sec_title">Conclusion</h2>
<p id="Par47">In conclusion, the present study revealed that GLP-1R gene expression in blood tissues (used to mimic the effects of GLP-1R agonists) is associated with a reduced risk of developing DR in a European population using the MR method as the primary analysis tool, and this conclusion is in agreement with the results of the SMR method-assisted analyses. We also conducted a systematic review of cohort studies in the context of European diabetic populations in order to explore the association of GLP-1R agonists with DR in the real world in a more in-depth and comprehensive manner; however, large clinical trials with more participants are needed in the future to explore the association of GLP-1R agonists with the risk of DR and to broaden the target of the study to include individuals who already have DR.</p></section><section id="Sec22"><h2 class="pmc_sec_title">Supplementary Information</h2>
<p>Below is the link to the electronic supplementary material.</p>
<section class="sm xbox font-sm" id="MOESM1"><div class="media p"><div class="caption">
<a href="/articles/instance/12366118/bin/13098_2025_1878_MOESM1_ESM.xlsx" data-ga-action="click_feat_suppl" class="usa-link">Supplementary Material 1</a><sup> (11.6KB, xlsx) </sup>
</div></div></section><section class="sm xbox font-sm" id="MOESM2"><div class="media p"><div class="caption">
<a href="/articles/instance/12366118/bin/13098_2025_1878_MOESM2_ESM.xlsx" data-ga-action="click_feat_suppl" class="usa-link">Supplementary Material 2</a><sup> (12.9KB, xlsx) </sup>
</div></div></section><section class="sm xbox font-sm" id="MOESM3"><div class="media p"><div class="caption">
<a href="/articles/instance/12366118/bin/13098_2025_1878_MOESM3_ESM.xlsx" data-ga-action="click_feat_suppl" class="usa-link">Supplementary Material 3</a><sup> (10.6KB, xlsx) </sup>
</div></div></section><section class="sm xbox font-sm" id="MOESM4"><div class="media p"><div class="caption">
<a href="/articles/instance/12366118/bin/13098_2025_1878_MOESM4_ESM.xlsx" data-ga-action="click_feat_suppl" class="usa-link">Supplementary Material 4</a><sup> (9.7KB, xlsx) </sup>
</div></div></section><section class="sm xbox font-sm" id="MOESM5"><div class="media p"><div class="caption">
<a href="/articles/instance/12366118/bin/13098_2025_1878_MOESM5_ESM.xlsx" data-ga-action="click_feat_suppl" class="usa-link">Supplementary Material 5</a><sup> (11.2KB, xlsx) </sup>
</div></div></section><section class="sm xbox font-sm" id="MOESM6"><div class="media p"><div class="caption">
<a href="/articles/instance/12366118/bin/13098_2025_1878_MOESM6_ESM.xlsx" data-ga-action="click_feat_suppl" class="usa-link">Supplementary Material 6</a><sup> (13.6KB, xlsx) </sup>
</div></div></section><section class="sm xbox font-sm" id="MOESM7"><div class="media p"><div class="caption">
<a href="/articles/instance/12366118/bin/13098_2025_1878_MOESM7_ESM.docx" data-ga-action="click_feat_suppl" class="usa-link">Supplementary Material 7</a><sup> (36.5KB, docx) </sup>
</div></div></section><section class="sm xbox font-sm" id="MOESM8"><div class="media p"><div class="caption">
<a href="/articles/instance/12366118/bin/13098_2025_1878_MOESM8_ESM.docx" data-ga-action="click_feat_suppl" class="usa-link">Supplementary Material 8</a><sup> (377.6KB, docx) </sup>
</div></div></section></section><section id="ack1" class="ack"><h2 class="pmc_sec_title">Acknowledgements</h2>
<p>Thanks to the developers of eQTLGen Consortium, GWAS catalog, FinnGen, UK Biobank, DIAGRAM Consortium database and related research participants. At the same time, we also thank the R software and SMR software developers for providing us with a free data analysis platform.</p></section><section id="notes1"><h2 class="pmc_sec_title">Author contributions</h2>
<p>B.S proposed research ideas and collected data; B.S and W.W wrote the manuscript. Y.G, Z.C, J.H, C.L, Y.L strictly examined and improved the manuscript.</p></section><section id="notes2"><h2 class="pmc_sec_title">Funding</h2>
<p>No Funding.</p></section><section id="notes3"><h2 class="pmc_sec_title">Data availability</h2>
<p>All data generated or analysed during this study are included in this published article [and its supplementary information files].</p></section><section id="notes4"><h2 class="pmc_sec_title">Declarations</h2>
<section id="FPar1"><h3 class="pmc_sec_title">Ethics approval and consent to participate</h3>
<p id="Par48">Not applicable.</p></section><section id="FPar2"><h3 class="pmc_sec_title">Consent for publication</h3>
<p id="Par49">Not applicable.</p></section><section id="FPar3"><h3 class="pmc_sec_title">Competing interests</h3>
<p id="Par50">The authors declare no competing interests.</p></section></section><section id="fn-group1" class="fn-group"><h2 class="pmc_sec_title">Footnotes</h2>
<div class="fn-group p font-secondary-light font-sm"><div class="fn p" id="fn1">
<p><strong>Publisher’s note</strong></p>
<p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
</div></div></section><section id="_ci93_" lang="en" class="contrib-info"><h2 class="pmc_sec_title">Contributor Information</h2>
<p>Jiarui Huang, Email: 522533841@qq.com.</p>
<p>Ying Li, Email: liying13552@163.com.</p></section><section id="Bib1" class="ref-list"><h2 class="pmc_sec_title">References</h2>
<section id="Bib1_sec2"><ul class="ref-list font-sm" style="list-style-type:none">
<li id="CR1">
<span class="label">1.</span><cite>Cole JB, Florez JC. Genetics of diabetes mellitus and diabetes complications. Nat Rev Nephrol. 2020;16(7):377–90.
</cite> [<a href="https://doi.org/10.1038/s41581-020-0278-5" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9639302/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32398868/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Cole%20JB,%20Florez%20JC.%20Genetics%20of%20diabetes%20mellitus%20and%20diabetes%20complications.%20Nat%20Rev%20Nephrol.%202020;16(7):377%E2%80%9390." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR2">
<span class="label">2.</span><cite>Teo ZL, Tham YC, Yu M, et al. Global prevalence of diabetic retinopathy and projection of burden through 2045: systematic review and meta-analysis. Ophthalmology. 2021;128(11):1580–91.
</cite> [<a href="https://doi.org/10.1016/j.ophtha.2021.04.027" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33940045/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Teo%20ZL,%20Tham%20YC,%20Yu%20M,%20et%20al.%20Global%20prevalence%20of%20diabetic%20retinopathy%20and%20projection%20of%20burden%20through%202045:%20systematic%20review%20and%20meta-analysis.%20Ophthalmology.%202021;128(11):1580%E2%80%9391." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR3">
<span class="label">3.</span><cite>Yao H, Zhang A, Li D, et al. Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis. BMJ. 2024;384:e076410.
</cite> [<a href="https://doi.org/10.1136/bmj-2023-076410" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10823535/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38286487/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Yao%20H,%20Zhang%20A,%20Li%20D,%20et%20al.%20Comparative%20effectiveness%20of%20GLP-1%20receptor%20agonists%20on%20glycaemic%20control,%20body%20weight,%20and%20lipid%20profile%20for%20type%202%20diabetes:%20systematic%20review%20and%20network%20meta-analysis.%20BMJ.%202024;384:e076410." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR4">
<span class="label">4.</span><cite>Clark L. GLP-1 receptor agonists: a review of glycemic benefits and beyond. JAAPA. 2024;37(4):1–4.
</cite> [<a href="https://doi.org/10.1097/01.JAA.0001007388.97793.41" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38531038/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Clark%20L.%20GLP-1%20receptor%20agonists:%20a%20review%20of%20glycemic%20benefits%20and%20beyond.%20JAAPA.%202024;37(4):1%E2%80%934." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR5">
<span class="label">5.</span><cite>Ma X, Liu Z, Ilyas I, et al. GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential. Int J Biol Sci. 2021;17(8):2050–68.
</cite> [<a href="https://doi.org/10.7150/ijbs.59965" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8193264/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34131405/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Ma%20X,%20Liu%20Z,%20Ilyas%20I,%20et%20al.%20GLP-1%20receptor%20agonists%20(GLP-1RAs):%20cardiovascular%20actions%20and%20therapeutic%20potential.%20Int%20J%20Biol%20Sci.%202021;17(8):2050%E2%80%9368." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR6">
<span class="label">6.</span><cite>Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–22.
</cite> [<a href="https://doi.org/10.1056/NEJMoa1603827" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4985288/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27295427/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Marso%20SP,%20Daniels%20GH,%20Brown-Frandsen%20K,%20et%20al.%20Liraglutide%20and%20cardiovascular%20outcomes%20in%20type%202%20diabetes.%20N%20Engl%20J%20Med.%202016;375(4):311%E2%80%9322." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR7">
<span class="label">7.</span><cite>Walker VM, Zheng J, Gaunt TR, et al. Phenotypic causal inference using genome-wide association study data: Mendelian randomization and beyond. Annu Rev Biomed Data Sci. 2022;5:1–17.
</cite> [<a href="https://doi.org/10.1146/annurev-biodatasci-122120-024910" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7614231/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35363507/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Walker%20VM,%20Zheng%20J,%20Gaunt%20TR,%20et%20al.%20Phenotypic%20causal%20inference%20using%20genome-wide%20association%20study%20data:%20Mendelian%20randomization%20and%20beyond.%20Annu%20Rev%20Biomed%20Data%20Sci.%202022;5:1%E2%80%9317." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR8">
<span class="label">8.</span><cite>Zhu Z, Zhang F, Hu H, et al. Integration of summary data from GWAS and eQTL studies predicts complex trait gene targets. Nat Genet. 2016;48(5):481–7.
</cite> [<a href="https://doi.org/10.1038/ng.3538" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27019110/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zhu%20Z,%20Zhang%20F,%20Hu%20H,%20et%20al.%20Integration%20of%20summary%20data%20from%20GWAS%20and%20eQTL%20studies%20predicts%20complex%20trait%20gene%20targets.%20Nat%20Genet.%202016;48(5):481%E2%80%937." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR9">
<span class="label">9.</span><cite>Võsa U, Claringbould A, Westra HJ, et al. Large-scale cis- and trans-eQTL analyses identify thousands of genetic loci and polygenic scores that regulate blood gene expression. Nat Genet. 2021;53(9):1300–10.
</cite> [<a href="https://doi.org/10.1038/s41588-021-00913-z" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8432599/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34475573/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?V%C3%B5sa%20U,%20Claringbould%20A,%20Westra%20HJ,%20et%20al.%20Large-scale%20cis-%20and%20trans-eQTL%20analyses%20identify%20thousands%20of%20genetic%20loci%20and%20polygenic%20scores%20that%20regulate%20blood%20gene%20expression.%20Nat%20Genet.%202021;53(9):1300%E2%80%9310." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR10">
<span class="label">10.</span><cite>Sekula P, Del Greco MF, Pattaro C, Köttgen A. Mendelian randomization as an approach to assess causality using observational data. J Am Soc Nephrol. 2016;27(11):3253–65.
</cite> [<a href="https://doi.org/10.1681/ASN.2016010098" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5084898/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27486138/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Sekula%20P,%20Del%20Greco%20MF,%20Pattaro%20C,%20K%C3%B6ttgen%20A.%20Mendelian%20randomization%20as%20an%20approach%20to%20assess%20causality%20using%20observational%20data.%20J%20Am%20Soc%20Nephrol.%202016;27(11):3253%E2%80%9365." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR11">
<span class="label">11.</span><cite>Nishi H, Nakata J, Kinoshita K. Distribution of single-nucleotide variants on protein-protein interaction sites and its relationship with minor allele frequency. Protein Sci. 2016;25(2):316–21.
</cite> [<a href="https://doi.org/10.1002/pro.2845" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4815344/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26580303/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Nishi%20H,%20Nakata%20J,%20Kinoshita%20K.%20Distribution%20of%20single-nucleotide%20variants%20on%20protein-protein%20interaction%20sites%20and%20its%20relationship%20with%20minor%20allele%20frequency.%20Protein%20Sci.%202016;25(2):316%E2%80%9321." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR12">
<span class="label">12.</span><cite>Lin SH, Brown DW, Machiela MJ. LDtrait: an online tool for identifying published phenotype associations in linkage disequilibrium. Cancer Res. 2020;80(16):3443–6.
</cite> [<a href="https://doi.org/10.1158/0008-5472.CAN-20-0985" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7442674/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32606005/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Lin%20SH,%20Brown%20DW,%20Machiela%20MJ.%20LDtrait:%20an%20online%20tool%20for%20identifying%20published%20phenotype%20associations%20in%20linkage%20disequilibrium.%20Cancer%20Res.%202020;80(16):3443%E2%80%936." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR13">
<span class="label">13.</span><cite>Bycroft C, Freeman C, Petkova D, et al. The UK biobank resource with deep phenotyping and genomic data. Nature. 2018;562(7726):203–9.
</cite> [<a href="https://doi.org/10.1038/s41586-018-0579-z" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6786975/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30305743/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Bycroft%20C,%20Freeman%20C,%20Petkova%20D,%20et%20al.%20The%20UK%20biobank%20resource%20with%20deep%20phenotyping%20and%20genomic%20data.%20Nature.%202018;562(7726):203%E2%80%939." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR14">
<span class="label">14.</span><cite>Mahajan A, Spracklen CN, Zhang W, et al. Multi-ancestry genetic study of type 2 diabetes highlights the power of diverse populations for discovery and translation. Nat Genet. 2022;54(5):560–72.
</cite> [<a href="https://doi.org/10.1038/s41588-022-01058-3" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9179018/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35551307/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Mahajan%20A,%20Spracklen%20CN,%20Zhang%20W,%20et%20al.%20Multi-ancestry%20genetic%20study%20of%20type%202%20diabetes%20highlights%20the%20power%20of%20diverse%20populations%20for%20discovery%20and%20translation.%20Nat%20Genet.%202022;54(5):560%E2%80%9372." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR15">
<span class="label">15.</span><cite>Zhou W, Nielsen JB, Fritsche LG, et al. Efficiently controlling for case-control imbalance and sample relatedness in large-scale genetic association studies. Nat Genet. 2018;50(9):1335–41.
</cite> [<a href="https://doi.org/10.1038/s41588-018-0184-y" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6119127/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30104761/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zhou%20W,%20Nielsen%20JB,%20Fritsche%20LG,%20et%20al.%20Efficiently%20controlling%20for%20case-control%20imbalance%20and%20sample%20relatedness%20in%20large-scale%20genetic%20association%20studies.%20Nat%20Genet.%202018;50(9):1335%E2%80%9341." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR16">
<span class="label">16.</span><cite>Zagkos L, Dib MJ, Pinto R, et al. Associations of genetically predicted fatty acid levels across the phenome: a Mendelian randomisation study. PLoS Med. 2022;19(12):e1004141.
</cite> [<a href="https://doi.org/10.1371/journal.pmed.1004141" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9799317/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36580444/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zagkos%20L,%20Dib%20MJ,%20Pinto%20R,%20et%20al.%20Associations%20of%20genetically%20predicted%20fatty%20acid%20levels%20across%20the%20phenome:%20a%20Mendelian%20randomisation%20study.%20PLoS%20Med.%202022;19(12):e1004141." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR17">
<span class="label">17.</span><cite>Zhao J, Ming J, Hu X, et al. Bayesian weighted Mendelian randomization for causal inference based on summary statistics. Bioinformatics. 2020;36(5):1501–8.
</cite> [<a href="https://doi.org/10.1093/bioinformatics/btz749" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31593215/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zhao%20J,%20Ming%20J,%20Hu%20X,%20et%20al.%20Bayesian%20weighted%20Mendelian%20randomization%20for%20causal%20inference%20based%20on%20summary%20statistics.%20Bioinformatics.%202020;36(5):1501%E2%80%938." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR18">
<span class="label">18.</span><cite>Su Y, Zhang Y, Xu J. Genetic variations in anti-diabetic drug targets and COPD risk: evidence from Mendelian randomization. BMC Pulm Med. 2024;24(1):240.
</cite> [<a href="https://doi.org/10.1186/s12890-024-02959-1" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11094874/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38750544/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Su%20Y,%20Zhang%20Y,%20Xu%20J.%20Genetic%20variations%20in%20anti-diabetic%20drug%20targets%20and%20COPD%20risk:%20evidence%20from%20Mendelian%20randomization.%20BMC%20Pulm%20Med.%202024;24(1):240." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR19">
<span class="label">19.</span><cite>Wallace C. Eliciting priors and relaxing the single causal variant assumption in colocalisation analyses. PLoS Genet. 2020;16(4):e1008720.
</cite> [<a href="https://doi.org/10.1371/journal.pgen.1008720" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7192519/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32310995/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Wallace%20C.%20Eliciting%20priors%20and%20relaxing%20the%20single%20causal%20variant%20assumption%20in%20colocalisation%20analyses.%20PLoS%20Genet.%202020;16(4):e1008720." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR20">
<span class="label">20.</span><cite>Grimes DA, Schulz KF. Cohort studies: marching towards outcomes. Lancet. 2002;359(9303):341–5.
</cite> [<a href="https://doi.org/10.1016/S0140-6736(02)07500-1" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/11830217/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Grimes%20DA,%20Schulz%20KF.%20Cohort%20studies:%20marching%20towards%20outcomes.%20Lancet.%202002;359(9303):341%E2%80%935." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR21">
<span class="label">21.</span><cite>Durlach V, Vergès B, Al-Salameh A, et al. Smoking and diabetes interplay: a comprehensive review and joint statement. Diabetes Metab. 2022;48(6):101370.
</cite> [<a href="https://doi.org/10.1016/j.diabet.2022.101370" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35779852/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Durlach%20V,%20Verg%C3%A8s%20B,%20Al-Salameh%20A,%20et%20al.%20Smoking%20and%20diabetes%20interplay:%20a%20comprehensive%20review%20and%20joint%20statement.%20Diabetes%20Metab.%202022;48(6):101370." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR22">
<span class="label">22.</span><cite>Borenstein M, Hedges LV, Higgins JP, et al. A basic introduction to fixed-effect and random-effects models for meta-analysis. Res Synth Methods. 2010;1(2):97–111.
</cite> [<a href="https://doi.org/10.1002/jrsm.12" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26061376/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Borenstein%20M,%20Hedges%20LV,%20Higgins%20JP,%20et%20al.%20A%20basic%20introduction%20to%20fixed-effect%20and%20random-effects%20models%20for%20meta-analysis.%20Res%20Synth%20Methods.%202010;1(2):97%E2%80%93111." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR23">
<span class="label">23.</span><cite>Kanters S. Fixed- and Random-Effects models. Methods Mol Biol. 2022;2345:41–65.
</cite> [<a href="https://doi.org/10.1007/978-1-0716-1566-9_3" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34550583/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Kanters%20S.%20Fixed-%20and%20Random-Effects%20models.%20Methods%20Mol%20Biol.%202022;2345:41%E2%80%9365." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR24">
<span class="label">24.</span><cite>Zhao SS, Yiu ZZN, Barton A, et al. Association of lipid-lowering drugs with risk of psoriasis: a Mendelian randomization study. JAMA Dermatol. 2023;159(3):344.
</cite> [<a href="https://doi.org/10.1001/jamadermatol.2022.6051" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9878432/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36696131/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zhao%20SS,%20Yiu%20ZZN,%20Barton%20A,%20et%20al.%20Association%20of%20lipid-lowering%20drugs%20with%20risk%20of%20psoriasis:%20a%20Mendelian%20randomization%20study.%20JAMA%20Dermatol.%202023;159(3):344." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR25">
<span class="label">25.</span><cite>Zuber V, Grinberg NF, Gill D, et al. Combining evidence from Mendelian randomization and colocalization: review and comparison of approaches. Am J Hum Genet. 2022;109(5):767–82.
</cite> [<a href="https://doi.org/10.1016/j.ajhg.2022.04.001" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7612737/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35452592/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zuber%20V,%20Grinberg%20NF,%20Gill%20D,%20et%20al.%20Combining%20evidence%20from%20Mendelian%20randomization%20and%20colocalization:%20review%20and%20comparison%20of%20approaches.%20Am%20J%20Hum%20Genet.%202022;109(5):767%E2%80%9382." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR26">
<span class="label">26.</span><cite>Ying K, Liu H, Tarkhov AE, et al. Causality-enriched epigenetic age uncouples damage and adaptation. Nat Aging. 2024;4(2):231–46.
</cite> [<a href="https://doi.org/10.1038/s43587-023-00557-0" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11070280/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38243142/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Ying%20K,%20Liu%20H,%20Tarkhov%20AE,%20et%20al.%20Causality-enriched%20epigenetic%20age%20uncouples%20damage%20and%20adaptation.%20Nat%20Aging.%202024;4(2):231%E2%80%9346." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR27">
<span class="label">27.</span><cite>Zheng D, Li N, Hou R, et al. Glucagon-like peptide-1 receptor agonists and diabetic retinopathy: nationwide cohort and Mendelian randomization studies. BMC Med. 2023;21(1):40.
</cite> [<a href="https://doi.org/10.1186/s12916-023-02753-6" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9898966/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36737746/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zheng%20D,%20Li%20N,%20Hou%20R,%20et%20al.%20Glucagon-like%20peptide-1%20receptor%20agonists%20and%20diabetic%20retinopathy:%20nationwide%20cohort%20and%20Mendelian%20randomization%20studies.%20BMC%20Med.%202023;21(1):40." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR28">
<span class="label">28.</span><cite>Douros A, Filion KB, Yin H, et al. Glucagon-like peptide 1 receptor agonists and the risk of incident diabetic retinopathy. Diabetes Care. 2018;41(11):2330–8.
</cite> [<a href="https://doi.org/10.2337/dc17-2280" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30150234/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Douros%20A,%20Filion%20KB,%20Yin%20H,%20et%20al.%20Glucagon-like%20peptide%201%20receptor%20agonists%20and%20the%20risk%20of%20incident%20diabetic%20retinopathy.%20Diabetes%20Care.%202018;41(11):2330%E2%80%938." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR29">
<span class="label">29.</span><cite>Hasselstrøm Jensen J, Vestergaard P, Hasselstrøm Jensen M. Association between glucose-lowering treatments and risk of diabetic retinopathy in people with type 2 diabetes: a nationwide cohort study. Curr Drug Saf. 2024;19(2):236–43.
</cite> [<a href="https://doi.org/10.2174/1574886318666230420084701" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37078347/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Hasselstr%C3%B8m%20Jensen%20J,%20Vestergaard%20P,%20Hasselstr%C3%B8m%20Jensen%20M.%20Association%20between%20glucose-lowering%20treatments%20and%20risk%20of%20diabetic%20retinopathy%20in%20people%20with%20type%202%20diabetes:%20a%20nationwide%20cohort%20study.%20Curr%20Drug%20Saf.%202024;19(2):236%E2%80%9343." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR30">
<span class="label">30.</span><cite>Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394(10193):121–30.
</cite> [<a href="https://doi.org/10.1016/S0140-6736(19)31149-3" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31189511/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Gerstein%20HC,%20Colhoun%20HM,%20Dagenais%20GR,%20et%20al.%20Dulaglutide%20and%20cardiovascular%20outcomes%20in%20type%202%20diabetes%20(REWIND):%20a%20double-blind,%20randomised%20placebo-controlled%20trial.%20Lancet.%202019;394(10193):121%E2%80%9330." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR31">
<span class="label">31.</span><cite>Voigt M, Schmidt S, Lehmann T, et al. Prevalence and progression rate of diabetic retinopathy in type 2 diabetes patients in correlation with the duration of diabetes. Exp Clin Endocrinol Diabetes. 2018;126(09):570–6.
</cite> [<a href="https://doi.org/10.1055/s-0043-120570" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29183104/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Voigt%20M,%20Schmidt%20S,%20Lehmann%20T,%20et%20al.%20Prevalence%20and%20progression%20rate%20of%20diabetic%20retinopathy%20in%20type%202%20diabetes%20patients%20in%20correlation%20with%20the%20duration%20of%20diabetes.%20Exp%20Clin%20Endocrinol%20Diabetes.%202018;126(09):570%E2%80%936." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR32">
<span class="label">32.</span><cite>Taylor R. Understanding the cause of type 2 diabetes. Lancet Diabetes Endocrinol. 2024;12(9):e18.</cite> [<a href="https://doi.org/10.1016/S2213-8587(24)00157-8" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39038473/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Taylor%20R.%20Understanding%20the%20cause%20of%20type%202%20diabetes.%20Lancet%20Diabetes%20Endocrinol.%202024;12(9):e18." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR33">
<span class="label">33.</span><cite>Nellaiappan K, Preeti K, Khatri DK, et al. Diabetic complications: an update on pathobiology and therapeutic strategies. Curr Diabetes Rev. 2022;18(1):e030821192146.
</cite> [<a href="https://doi.org/10.2174/1573399817666210309104203" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33745424/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Nellaiappan%20K,%20Preeti%20K,%20Khatri%20DK,%20et%20al.%20Diabetic%20complications:%20an%20update%20on%20pathobiology%20and%20therapeutic%20strategies.%20Curr%20Diabetes%20Rev.%202022;18(1):e030821192146." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR34">
<span class="label">34.</span><cite>Tan TE, Wong TY. Diabetic retinopathy: looking forward to 2030. Front Endocrinol. 2023;13:1077669.</cite> [<a href="https://doi.org/10.3389/fendo.2022.1077669" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9868457/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36699020/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Tan%20TE,%20Wong%20TY.%20Diabetic%20retinopathy:%20looking%20forward%20to%202030.%20Front%20Endocrinol.%202023;13:1077669." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR35">
<span class="label">35.</span><cite>Camilleri M, Acosta A. Newer pharmacological interventions directed at gut hormones for obesity. Br J Pharmacol. 2024;181(8):1153–64.
</cite> [<a href="https://doi.org/10.1111/bph.16278" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10947960/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37917871/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Camilleri%20M,%20Acosta%20A.%20Newer%20pharmacological%20interventions%20directed%20at%20gut%20hormones%20for%20obesity.%20Br%20J%20Pharmacol.%202024;181(8):1153%E2%80%9364." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR36">
<span class="label">36.</span><cite>Rosenfeld RM, Grega ML, Gulati M. Lifestyle interventions for treatment and remission of type 2 diabetes and prediabetes in adults: implications for clinicians. Am J Lifestyle Med. 2025 10.1177/15598276251325802.</cite> [<a href="https://doi.org/10.1177/15598276251325802" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11949759/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/40161282/" class="usa-link">PubMed</a>]</li>
<li id="CR37">
<span class="label">37.</span><cite>Młynarska E, Czarnik W, Dzieża N, et al. Type 2 diabetes mellitus: new pathogenetic mechanisms, treatment and the most important complications. Int J Mol Sci. 2025;26(3):1094.
</cite> [<a href="https://doi.org/10.3390/ijms26031094" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11817707/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39940862/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?M%C5%82ynarska%20E,%20Czarnik%20W,%20Dzie%C5%BCa%20N,%20et%20al.%20Type%202%20diabetes%20mellitus:%20new%20pathogenetic%20mechanisms,%20treatment%20and%20the%20most%20important%20complications.%20Int%20J%20Mol%20Sci.%202025;26(3):1094." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR38">
<span class="label">38.</span><cite>ElSayed NA, McCoy RG, Aleppo G et al. 9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes—2025. Diabetes Care. 2025;48.</cite> [<a href="https://doi.org/10.2337/dc25-S009" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11635045/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39651989/" class="usa-link">PubMed</a>]</li>
<li id="CR39">
<span class="label">39.</span><cite>Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834–44.
</cite> [<a href="https://doi.org/10.1056/NEJMoa1607141" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27633186/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Marso%20SP,%20Bain%20SC,%20Consoli%20A,%20et%20al.%20Semaglutide%20and%20cardiovascular%20outcomes%20in%20patients%20with%20type%202%20diabetes.%20N%20Engl%20J%20Med.%202016;375(19):1834%E2%80%9344." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR40">
<span class="label">40.</span><cite>Vasu P, Dorairaj EA, Weinreb RN, et al. Risk of glaucoma in patients without diabetes using a glucagon-like peptide 1 receptor agonist. Ophthalmology. 2025;S0161–6420(25):00132–0.</cite> [<a href="https://doi.org/10.1016/j.ophtha.2025.02.011" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39978437/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Vasu%20P,%20Dorairaj%20EA,%20Weinreb%20RN,%20et%20al.%20Risk%20of%20glaucoma%20in%20patients%20without%20diabetes%20using%20a%20glucagon-like%20peptide%201%20receptor%20agonist.%20Ophthalmology.%202025;S0161%E2%80%936420(25):00132%E2%80%930." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR41">
<span class="label">41.</span><cite>Gallwitz B. Glucagon-like peptide-1-based therapies for the treatment of type 2 diabetes mellitus. Treat Endocrinol. 2005;4:361–70.
</cite> [<a href="https://doi.org/10.2165/00024677-200504060-00005" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/16318402/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Gallwitz%20B.%20Glucagon-like%20peptide-1-based%20therapies%20for%20the%20treatment%20of%20type%202%20diabetes%20mellitus.%20Treat%20Endocrinol.%202005;4:361%E2%80%9370." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR42">
<span class="label">42.</span><cite>Husain M, Birkenfeld AL, Donsmark M, et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2019;381(9):841–51.
</cite> [<a href="https://doi.org/10.1056/NEJMoa1901118" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31185157/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Husain%20M,%20Birkenfeld%20AL,%20Donsmark%20M,%20et%20al.%20Oral%20semaglutide%20and%20cardiovascular%20outcomes%20in%20patients%20with%20type%202%20diabetes.%20N%20Engl%20J%20Med.%202019;381(9):841%E2%80%9351." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR43">
<span class="label">43.</span><cite>Malik IO, Petersen MC, Klein S. Glucagon-like peptide‐1, glucose‐dependent insulinotropic polypeptide, and glucagon receptor poly‐agonists: a new era in obesity pharmacotherapy. Obesity. 2022;30(9):1718–21.
</cite> [<a href="https://doi.org/10.1002/oby.23521" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9420816/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35872608/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Malik%20IO,%20Petersen%20MC,%20Klein%20S.%20Glucagon-like%20peptide%E2%80%901,%20glucose%E2%80%90dependent%20insulinotropic%20polypeptide,%20and%20glucagon%20receptor%20poly%E2%80%90agonists:%20a%20new%20era%20in%20obesity%20pharmacotherapy.%20Obesity.%202022;30(9):1718%E2%80%9321." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR44">
<span class="label">44.</span><cite>Alhomoud IS, Talasaz AH, Chandrasekaran P, et al. Incretin hormone agonists: current and emerging pharmacotherapy for obesity management. Pharmacotherapy. 2024;44(9):738–52.
</cite> [<a href="https://doi.org/10.1002/phar.4607" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39225417/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Alhomoud%20IS,%20Talasaz%20AH,%20Chandrasekaran%20P,%20et%20al.%20Incretin%20hormone%20agonists:%20current%20and%20emerging%20pharmacotherapy%20for%20obesity%20management.%20Pharmacotherapy.%202024;44(9):738%E2%80%9352." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR45">
<span class="label">45.</span><cite>Liu QK. Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists. Front Endocrinol. 2024;15:1431292.</cite> [<a href="https://doi.org/10.3389/fendo.2024.1431292" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11304055/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39114288/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Liu%20QK.%20Mechanisms%20of%20action%20and%20therapeutic%20applications%20of%20GLP-1%20and%20dual%20GIP/GLP-1%20receptor%20agonists.%20Front%20Endocrinol.%202024;15:1431292." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR46">
<span class="label">46.</span><cite>Shyam M, Sidharth S, Veronica A, et al. Diabetic retinopathy: a comprehensive review of pathophysiology and emerging treatments. Mol Biol Rep. 2025;52(1):380.
</cite> [<a href="https://doi.org/10.1007/s11033-025-10490-7" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/40205024/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Shyam%20M,%20Sidharth%20S,%20Veronica%20A,%20et%20al.%20Diabetic%20retinopathy:%20a%20comprehensive%20review%20of%20pathophysiology%20and%20emerging%20treatments.%20Mol%20Biol%20Rep.%202025;52(1):380." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR47">
<span class="label">47.</span><cite>Seo H, Park SJ, Song M. Diabetic retinopathy (DR): mechanisms, current therapies, and emerging strategies. Cells. 2025;14(5):376.
</cite> [<a href="https://doi.org/10.3390/cells14050376" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11898816/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/40072104/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Seo%20H,%20Park%20SJ,%20Song%20M.%20Diabetic%20retinopathy%20(DR):%20mechanisms,%20current%20therapies,%20and%20emerging%20strategies.%20Cells.%202025;14(5):376." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR48">
<span class="label">48.</span><cite>He X, Wen S, Tang X, et al. Glucagon-like peptide-1 receptor agonists rescued diabetic vascular endothelial damage through suppression of aberrant STING signaling. Acta Pharm Sin B. 2024;14(6):2613–30.
</cite> [<a href="https://doi.org/10.1016/j.apsb.2024.03.011" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11143538/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38828140/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?He%20X,%20Wen%20S,%20Tang%20X,%20et%20al.%20Glucagon-like%20peptide-1%20receptor%20agonists%20rescued%20diabetic%20vascular%20endothelial%20damage%20through%20suppression%20of%20aberrant%20STING%20signaling.%20Acta%20Pharm%20Sin%20B.%202024;14(6):2613%E2%80%9330." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR49">
<span class="label">49.</span><cite>Puddu A, Maggi D. Anti-inflammatory effects of GLP-1R activation in the retina. Int J Mol Sci. 2022;23(20):12428.
</cite> [<a href="https://doi.org/10.3390/ijms232012428" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9604172/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36293281/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Puddu%20A,%20Maggi%20D.%20Anti-inflammatory%20effects%20of%20GLP-1R%20activation%20in%20the%20retina.%20Int%20J%20Mol%20Sci.%202022;23(20):12428." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR50">
<span class="label">50.</span><cite>Chen H, Zhang X, Liao N, et al. Decreased expression of glucagon-like peptide-1 receptor and sodium-glucose co-transporter 2 in patients with proliferative diabetic retinopathy. Front Endocrinol. 2022;13:1020252.</cite> [<a href="https://doi.org/10.3389/fendo.2022.1020252" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9712753/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36465606/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Chen%20H,%20Zhang%20X,%20Liao%20N,%20et%20al.%20Decreased%20expression%20of%20glucagon-like%20peptide-1%20receptor%20and%20sodium-glucose%20co-transporter%202%20in%20patients%20with%20proliferative%20diabetic%20retinopathy.%20Front%20Endocrinol.%202022;13:1020252." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR51">
<span class="label">51.</span><cite>Guo Z. The role of glucagon-like peptide-1/GLP-1R and autophagy in diabetic cardiovascular disease. Pharmacol Rep. 2024;76(4):754–79.
</cite> [<a href="https://doi.org/10.1007/s43440-024-00609-1" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38890260/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Guo%20Z.%20The%20role%20of%20glucagon-like%20peptide-1/GLP-1R%20and%20autophagy%20in%20diabetic%20cardiovascular%20disease.%20Pharmacol%20Rep.%202024;76(4):754%E2%80%9379." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR52">
<span class="label">52.</span><cite>Wei L, Mo W, Lan S et al. GLP-1 RA improves diabetic retinopathy by protecting the blood‐retinal barrier through GLP‐1R‐ROCK‐p‐MLC signaling pathway. Diabetes Res. 2022;2022:1861940.</cite> [<a href="https://doi.org/10.1155/2022/1861940" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9649324/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36387940/" class="usa-link">PubMed</a>]</li>
<li id="CR53">
<span class="label">53.</span><cite>Hussain A, Ashique S, Afzal O, et al. A correlation between oxidative stress and diabetic retinopathy: an updated review. Exp Eye Res. 2023;236:109650.
</cite> [<a href="https://doi.org/10.1016/j.exer.2023.109650" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37734426/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Hussain%20A,%20Ashique%20S,%20Afzal%20O,%20et%20al.%20A%20correlation%20between%20oxidative%20stress%20and%20diabetic%20retinopathy:%20an%20updated%20review.%20Exp%20Eye%20Res.%202023;236:109650." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR54">
<span class="label">54.</span><cite>Zeng Y, Yang K, Wang F, et al. The glucagon like peptide 1 analogue, exendin-4, attenuates oxidative stress-induced retinal cell death in early diabetic rats through promoting Sirt1 and Sirt3 expression. Exp Eye Res. 2016;151:203–11.
</cite> [<a href="https://doi.org/10.1016/j.exer.2016.05.002" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27212443/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zeng%20Y,%20Yang%20K,%20Wang%20F,%20et%20al.%20The%20glucagon%20like%20peptide%201%20analogue,%20exendin-4,%20attenuates%20oxidative%20stress-induced%20retinal%20cell%20death%20in%20early%20diabetic%20rats%20through%20promoting%20Sirt1%20and%20Sirt3%20expression.%20Exp%20Eye%20Res.%202016;151:203%E2%80%9311." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR55">
<span class="label">55.</span><cite>Kang Q, Yang C. Oxidative stress and diabetic retinopathy: molecular mechanisms, pathogenetic role and therapeutic implications. Redox Biol. 2020;37:101799.
</cite> [<a href="https://doi.org/10.1016/j.redox.2020.101799" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7767789/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33248932/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Kang%20Q,%20Yang%20C.%20Oxidative%20stress%20and%20diabetic%20retinopathy:%20molecular%20mechanisms,%20pathogenetic%20role%20and%20therapeutic%20implications.%20Redox%20Biol.%202020;37:101799." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR56">
<span class="label">56.</span><cite>Kim DI, Park MJ, Choi JH, et al. Hyperglycemia-induced GLP-1R downregulation causes RPE cell apoptosis. Int J Biochem Cell Biol. 2015;59:41–51.
</cite> [<a href="https://doi.org/10.1016/j.biocel.2014.11.018" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25483438/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Kim%20DI,%20Park%20MJ,%20Choi%20JH,%20et%20al.%20Hyperglycemia-induced%20GLP-1R%20downregulation%20causes%20RPE%20cell%20apoptosis.%20Int%20J%20Biochem%20Cell%20Biol.%202015;59:41%E2%80%9351." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR57">
<span class="label">57.</span><cite>Cai X, Li J, Wang M, et al. GLP-1 treatment improves diabetic retinopathy by alleviating autophagy through GLP-1R-ERK1/2-HDAC6 signaling pathway. Int J Med Sci. 2017;14(12):1203.
</cite> [<a href="https://doi.org/10.7150/ijms.20962" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5666553/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29104476/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Cai%20X,%20Li%20J,%20Wang%20M,%20et%20al.%20GLP-1%20treatment%20improves%20diabetic%20retinopathy%20by%20alleviating%20autophagy%20through%20GLP-1R-ERK1/2-HDAC6%20signaling%20pathway.%20Int%20J%20Med%20Sci.%202017;14(12):1203." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR58">
<span class="label">58.</span><cite>Ma X, Lin W, Lin Z, et al. Liraglutide alleviates H2O2-induced retinal ganglion cells injury by inhibiting autophagy through mitochondrial pathways. Peptides. 2017;92:1–8.
</cite> [<a href="https://doi.org/10.1016/j.peptides.2017.04.008" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28450048/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Ma%20X,%20Lin%20W,%20Lin%20Z,%20et%20al.%20Liraglutide%20alleviates%20H2O2-induced%20retinal%20ganglion%20cells%20injury%20by%20inhibiting%20autophagy%20through%20mitochondrial%20pathways.%20Peptides.%202017;92:1%E2%80%938." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR59">
<span class="label">59.</span><cite>Antonetti DA, Klein R, Gardner TW. Diabetic retinopathy. N Engl J Med. 2012;366(13):1227–39.
</cite> [<a href="https://doi.org/10.1056/NEJMra1005073" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22455417/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Antonetti%20DA,%20Klein%20R,%20Gardner%20TW.%20Diabetic%20retinopathy.%20N%20Engl%20J%20Med.%202012;366(13):1227%E2%80%9339." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR60">
<span class="label">60.</span><cite>Simo R, Hernández C. Neurodegeneration in the diabetic eye: new insights and therapeutic perspectives. Trends Endocrinol Metab. 2014;25(1):23–33.
</cite> [<a href="https://doi.org/10.1016/j.tem.2013.09.005" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24183659/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Simo%20R,%20Hern%C3%A1ndez%20C.%20Neurodegeneration%20in%20the%20diabetic%20eye:%20new%20insights%20and%20therapeutic%20perspectives.%20Trends%20Endocrinol%20Metab.%202014;25(1):23%E2%80%9333." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR61">
<span class="label">61.</span><cite>Hebsgaard JB, Pyke C, Yildirim E, et al. Glucagon-like peptide‐1 receptor expression in the human eye. Diabetes Obes Metab. 2018;20(9):2304–8.
</cite> [<a href="https://doi.org/10.1111/dom.13339" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6099507/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29707863/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Hebsgaard%20JB,%20Pyke%20C,%20Yildirim%20E,%20et%20al.%20Glucagon-like%20peptide%E2%80%901%20receptor%20expression%20in%20the%20human%20eye.%20Diabetes%20Obes%20Metab.%202018;20(9):2304%E2%80%938." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR62">
<span class="label">62.</span><cite>Hernández C, Bogdanov P, Corraliza L, et al. Topical administration of GLP-1 receptor agonists prevents retinal neurodegeneration in experimental diabetes. Diabetes. 2016;65(1):172–87.
</cite> [<a href="https://doi.org/10.2337/db15-0443" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26384381/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Hern%C3%A1ndez%20C,%20Bogdanov%20P,%20Corraliza%20L,%20et%20al.%20Topical%20administration%20of%20GLP-1%20receptor%20agonists%20prevents%20retinal%20neurodegeneration%20in%20experimental%20diabetes.%20Diabetes.%202016;65(1):172%E2%80%9387." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR63">
<span class="label">63.</span><cite>Wang YC, Wang L, Shao YQ, et al. Exendin-4 promotes retinal ganglion cell survival and function by inhibiting calcium channels in experimental diabetes. Iscience. 2023;26(9):107680.
</cite> [<a href="https://doi.org/10.1016/j.isci.2023.107680" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10481356/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37680468/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Wang%20YC,%20Wang%20L,%20Shao%20YQ,%20et%20al.%20Exendin-4%20promotes%20retinal%20ganglion%20cell%20survival%20and%20function%20by%20inhibiting%20calcium%20channels%20in%20experimental%20diabetes.%20Iscience.%202023;26(9):107680." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR64">
<span class="label">64.</span><cite>Simó R, Hernández C. GLP-1R as a target for the treatment of diabetic retinopathy: friend or foe? Diabetes. 2017;66(6):1453–60.
</cite> [<a href="https://doi.org/10.2337/db16-1364" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28533296/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Sim%C3%B3%20R,%20Hern%C3%A1ndez%20C.%20GLP-1R%20as%20a%20target%20for%20the%20treatment%20of%20diabetic%20retinopathy:%20friend%20or%20foe?%20Diabetes.%202017;66(6):1453%E2%80%9360." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR65">
<span class="label">65.</span><cite>Shu X, Zhang Y, Li M, et al. Topical ocular administration of the GLP-1 receptor agonist liraglutide arrests hyperphosphorylated tau-triggered diabetic retinal neurodegeneration via activation of GLP-1R/Akt/GSK3β signaling. Neuropharmacology. 2019;153:1–12.
</cite> [<a href="https://doi.org/10.1016/j.neuropharm.2019.04.018" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31015047/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Shu%20X,%20Zhang%20Y,%20Li%20M,%20et%20al.%20Topical%20ocular%20administration%20of%20the%20GLP-1%20receptor%20agonist%20liraglutide%20arrests%20hyperphosphorylated%20tau-triggered%20diabetic%20retinal%20neurodegeneration%20via%20activation%20of%20GLP-1R/Akt/GSK3%CE%B2%20signaling.%20Neuropharmacology.%202019;153:1%E2%80%9312." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR66">
<span class="label">66.</span><cite>Shao YQ, Wang YC, Wang L, et al. Topical administration of GLP-1 eyedrops improves retinal ganglion cell function by facilitating presynaptic GABA release in early experimental diabetes. Neural Regen Res. 2026;21(2):800–10.
</cite> [<a href="https://doi.org/10.4103/NRR.NRR-D-24-00001" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC12220725/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38934389/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Shao%20YQ,%20Wang%20YC,%20Wang%20L,%20et%20al.%20Topical%20administration%20of%20GLP-1%20eyedrops%20improves%20retinal%20ganglion%20cell%20function%20by%20facilitating%20presynaptic%20GABA%20release%20in%20early%20experimental%20diabetes.%20Neural%20Regen%20Res.%202026;21(2):800%E2%80%9310." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR67">
<span class="label">67.</span><cite>Fan Y, Liu K, Wang Q, et al. Exendin-4 alleviates retinal vascular leakage by protecting the blood–retinal barrier and reducing retinal vascular permeability in diabetic Goto-Kakizaki rats. Exp Eye Res. 2014;127:104–16.
</cite> [<a href="https://doi.org/10.1016/j.exer.2014.05.004" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24910901/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Fan%20Y,%20Liu%20K,%20Wang%20Q,%20et%20al.%20Exendin-4%20alleviates%20retinal%20vascular%20leakage%20by%20protecting%20the%20blood%E2%80%93retinal%20barrier%20and%20reducing%20retinal%20vascular%20permeability%20in%20diabetic%20Goto-Kakizaki%20rats.%20Exp%20Eye%20Res.%202014;127:104%E2%80%9316." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR68">
<span class="label">68.</span><cite>Varadhan L, Humphreys T, Walker AB, et al. The impact of improved glycaemic control with GLP-1 receptor agonist therapy on diabetic retinopathy. Diabetes Res Clin Pract. 2014;103(3):e37–9.
</cite> [<a href="https://doi.org/10.1016/j.diabres.2013.12.041" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24456992/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Varadhan%20L,%20Humphreys%20T,%20Walker%20AB,%20et%20al.%20The%20impact%20of%20improved%20glycaemic%20control%20with%20GLP-1%20receptor%20agonist%20therapy%20on%20diabetic%20retinopathy.%20Diabetes%20Res%20Clin%20Pract.%202014;103(3):e37%E2%80%939." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR69">
<span class="label">69.</span><cite>Eleftheriadou A, Riley D, Zhao SS, et al. Risk of diabetic retinopathy and diabetic macular oedema with sodium–glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists in type 2 diabetes: a real-world data study from a global federated database. Diabetologia. 2024;67(7):1271–82.
</cite> [<a href="https://doi.org/10.1007/s00125-024-06132-5" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11153282/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38584180/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Eleftheriadou%20A,%20Riley%20D,%20Zhao%20SS,%20et%20al.%20Risk%20of%20diabetic%20retinopathy%20and%20diabetic%20macular%20oedema%20with%20sodium%E2%80%93glucose%20cotransporter%202%20inhibitors%20and%20glucagon-like%20peptide%201%20receptor%20agonists%20in%20type%202%20diabetes:%20a%20real-world%20data%20study%20from%20a%20global%20federated%20database.%20Diabetologia.%202024;67(7):1271%E2%80%9382." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR70">
<span class="label">70.</span><cite>Bethel MA, Diaz R, Castellana N, et al. HbA1c change and diabetic retinopathy during GLP-1 receptor agonist cardiovascular outcome trials: a meta-analysis and meta-regression. Diabetes Care. 2021;44(1):290–6.
</cite> [<a href="https://doi.org/10.2337/dc20-1815" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7783944/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33444163/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Bethel%20MA,%20Diaz%20R,%20Castellana%20N,%20et%20al.%20HbA1c%20change%20and%20diabetic%20retinopathy%20during%20GLP-1%20receptor%20agonist%20cardiovascular%20outcome%20trials:%20a%20meta-analysis%20and%20meta-regression.%20Diabetes%20Care.%202021;44(1):290%E2%80%936." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR71">
<span class="label">71.</span><cite>Xie L, Peng YQ, Shen X. Identifying therapeutic target genes for diabetic retinopathy using systematic druggable genome-wide Mendelian randomization. Diabetol Metab Syndr. 2025;17(1):145.
</cite> [<a href="https://doi.org/10.1186/s13098-025-01710-y" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC12039192/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/40301928/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Xie%20L,%20Peng%20YQ,%20Shen%20X.%20Identifying%20therapeutic%20target%20genes%20for%20diabetic%20retinopathy%20using%20systematic%20druggable%20genome-wide%20Mendelian%20randomization.%20Diabetol%20Metab%20Syndr.%202025;17(1):145." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR72">
<span class="label">72.</span><cite>Chen C, Zhang H, Lan Y, et al. Statins as a risk factor for diabetic retinopathy: a Mendelian randomization and cross-sectional observational study. J Transl Med. 2024;22(1):298.
</cite> [<a href="https://doi.org/10.1186/s12967-024-05097-8" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10958895/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38520016/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Chen%20C,%20Zhang%20H,%20Lan%20Y,%20et%20al.%20Statins%20as%20a%20risk%20factor%20for%20diabetic%20retinopathy:%20a%20Mendelian%20randomization%20and%20cross-sectional%20observational%20study.%20J%20Transl%20Med.%202024;22(1):298." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
</ul></section></section><section id="_ad93_" lang="en" class="associated-data"><h2 class="pmc_sec_title">Associated Data</h2>
<p class="font-secondary"><em>This section collects any data citations, data availability statements, or supplementary materials included in this article.</em></p>
<section id="_adsm93_" lang="en" class="supplementary-materials"><h3 class="pmc_sec_title">Supplementary Materials</h3>
<section class="sm xbox font-sm" id="db_ds_supplementary-material1_reqid_"><div class="media p"><div class="caption">
<a href="/articles/instance/12366118/bin/13098_2025_1878_MOESM1_ESM.xlsx" data-ga-action="click_feat_suppl" class="usa-link">Supplementary Material 1</a><sup> (11.6KB, xlsx) </sup>
</div></div></section><section class="sm xbox font-sm" id="db_ds_supplementary-material2_reqid_"><div class="media p"><div class="caption">
<a href="/articles/instance/12366118/bin/13098_2025_1878_MOESM2_ESM.xlsx" data-ga-action="click_feat_suppl" class="usa-link">Supplementary Material 2</a><sup> (12.9KB, xlsx) </sup>
</div></div></section><section class="sm xbox font-sm" id="db_ds_supplementary-material3_reqid_"><div class="media p"><div class="caption">
<a href="/articles/instance/12366118/bin/13098_2025_1878_MOESM3_ESM.xlsx" data-ga-action="click_feat_suppl" class="usa-link">Supplementary Material 3</a><sup> (10.6KB, xlsx) </sup>
</div></div></section><section class="sm xbox font-sm" id="db_ds_supplementary-material4_reqid_"><div class="media p"><div class="caption">
<a href="/articles/instance/12366118/bin/13098_2025_1878_MOESM4_ESM.xlsx" data-ga-action="click_feat_suppl" class="usa-link">Supplementary Material 4</a><sup> (9.7KB, xlsx) </sup>
</div></div></section><section class="sm xbox font-sm" id="db_ds_supplementary-material5_reqid_"><div class="media p"><div class="caption">
<a href="/articles/instance/12366118/bin/13098_2025_1878_MOESM5_ESM.xlsx" data-ga-action="click_feat_suppl" class="usa-link">Supplementary Material 5</a><sup> (11.2KB, xlsx) </sup>
</div></div></section><section class="sm xbox font-sm" id="db_ds_supplementary-material6_reqid_"><div class="media p"><div class="caption">
<a href="/articles/instance/12366118/bin/13098_2025_1878_MOESM6_ESM.xlsx" data-ga-action="click_feat_suppl" class="usa-link">Supplementary Material 6</a><sup> (13.6KB, xlsx) </sup>
</div></div></section><section class="sm xbox font-sm" id="db_ds_supplementary-material7_reqid_"><div class="media p"><div class="caption">
<a href="/articles/instance/12366118/bin/13098_2025_1878_MOESM7_ESM.docx" data-ga-action="click_feat_suppl" class="usa-link">Supplementary Material 7</a><sup> (36.5KB, docx) </sup>
</div></div></section><section class="sm xbox font-sm" id="db_ds_supplementary-material8_reqid_"><div class="media p"><div class="caption">
<a href="/articles/instance/12366118/bin/13098_2025_1878_MOESM8_ESM.docx" data-ga-action="click_feat_suppl" class="usa-link">Supplementary Material 8</a><sup> (377.6KB, docx) </sup>
</div></div></section></section><section id="_adda93_" lang="en" class="data-availability-statement"><h3 class="pmc_sec_title">Data Availability Statement</h3>
<p>All data generated or analysed during this study are included in this published article [and its supplementary information files].</p></section></section></section><footer class="p courtesy-note font-secondary font-sm text-center"><hr class="headless">
<p>Articles from Diabetology &amp; Metabolic Syndrome are provided here courtesy of <strong>BMC</strong></p></footer></section></article>

                      

                    </main>
                </div>
            </div>
        </div>

        



<!-- Secondary navigation placeholder -->
<div class="pmc-sidenav desktop:grid-col-4 display-flex">
    <section class="pmc-sidenav__container" aria-label="Article resources and navigation">
        <button type="button" class="usa-button pmc-sidenav__container__close usa-button--unstyled">
            <img src="/static/img/usa-icons/close.svg" role="img" alt="Close" />
        </button>
    <div class="display-none desktop:display-block">
       <section class="margin-top-4 desktop:margin-top-0">
              <h2 class="margin-top-0">ACTIONS</h2>
           <ul class="usa-list usa-list--unstyled usa-list--actions">
               
               <li>
                     <a
                             href="https://doi.org/10.1186/s13098-025-01878-3"
                             class="usa-button usa-button--outline width-24 font-xs display-inline-flex flex-align-center flex-justify-start padding-left-1"
                             target="_blank"
                             rel="noreferrer noopener"
                             data-ga-category="actions"
                             data-ga-action="click"
                             data-ga-label="publisher_link_desktop"
                     >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#launch"></use>
                         </svg>
                         <span class="display-inline-flex flex-justify-center flex-1 padding-right-2">View on publisher site</span>
                     </a>
               </li>
               
               
               <li>
                    <a
                            href="pdf/13098_2025_Article_1878.pdf"
                            class="usa-button usa-button--outline width-24 display-inline-flex flex-align-center flex-justify-start padding-left-1"
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="pdf_download_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#file_download"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1">PDF (2.8 MB)</span>
                    </a>
               </li>
               
                
               <li>
                   <button role="button" class="usa-button width-24 citation-dialog-trigger display-inline-flex flex-align-center flex-justify-start padding-left-1"
                        aria-label="Open dialog with citation text in different styles"
                        data-ga-category="actions"
                        data-ga-action="open"
                        data-ga-label="cite_desktop"
                        data-all-citations-url="/resources/citations/12366118/"
                        data-citation-style="nlm"
                        data-download-format-link="/resources/citations/12366118/export/"
                    >
                        <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                        </svg>
                       <span class="display-inline-flex flex-justify-center flex-1 button-label">Cite</span>
                    </button>
               </li>
                
               <li>

                        <button class="usa-button width-24 collections-dialog-trigger collections-button display-inline-flex flex-align-center flex-justify-start padding-left-1 collections-button-empty"
                              aria-label="Save article in MyNCBI collections."
                              data-ga-category="actions"
                              data-ga-action="click"
                              data-ga-label="collections_button_desktop"
                              data-collections-open-dialog-enabled="false"
                              data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12366118%2F%3Freport%3Dclassic%23open-collections-dialog"
                              data-in-collections="false">
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                            <span class="display-inline-flex flex-justify-center flex-1">Collections</span>
                       </button>
               </li>
               <li class="pmc-permalink">
                    <button
                            type="button"
                            class="usa-button width-24 display-inline-flex flex-align-center flex-justify padding-left-1 shadow-none"
                            aria-label="Show article permalink"
                            aria-expanded="false"
                            aria-haspopup="true"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="permalink_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#share"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1 button-label">Permalink</span>
                    </button>
                   

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12366118/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
               </li>
           </ul>
       </section>
     </div>

        <section class="pmc-resources margin-top-6 desktop:margin-top-4" data-page-path="/articles/PMC12366118/">
            <h2 class="margin-top-0">RESOURCES</h2>
            
                <div class="usa-accordion usa-accordion--multiselectable" data-allow-multiple>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-similar-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_similar_articles"
                        data-ga-label="/articles/PMC12366118/"
                        data-action-open="open_similar_articles"
                        data-action-close="close_similar_articles"
                        >
                            Similar articles
                        </button>
                    </h3>
                    <div
                            id="resources-similar-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/similar-article-links/40830891/"
                            
                    >
                        
                    </div>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-cited-by-other-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_cited_by"
                        data-ga-label="/articles/PMC12366118/"
                        data-action-open="open_cited_by"
                        data-action-close="close_cited_by"
                        >
                             Cited by other articles
                        </button>
                    </h3>
                    <div
                            id="resources-cited-by-other-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/cited-by-links/40830891/"
                            
                    >
                          
                    </div>
                    
                        <h3 class="usa-accordion__heading">
                            <button
                            type="button"
                            class="usa-accordion__button"
                            aria-expanded="false"
                            aria-controls="resources-links-to-ncbi-databases"
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/articles/PMC12366118/"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                            >
                                 Links to NCBI Databases
                            </button>
                        </h3>
                        <div
                                id="resources-links-to-ncbi-databases"
                                class="usa-accordion__content usa-prose"
                                data-source-url="/resources/db-links/12366118/"
                        >
                        </div>
                    
                    
                </div>
            
        </section>


        <section
        class="usa-in-page-nav usa-in-page-nav--wide margin-top-6 desktop:margin-top-4"
        data-title-text="On this page"
        data-title-heading-level="h2"
        data-scroll-offset="0"
        data-root-margin="-10% 0px -80% 0px"
        data-main-content-selector="main"
        data-threshold="1"
        hidden
        ></section>
    </section>
</div>


        

<div class="overlay" role="dialog" aria-label="Citation Dialog" hidden>
    <div class="dialog citation-dialog" aria-hidden="true">
        <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
            <h2 class="usa-modal__heading margin-0">Cite</h2>
             <button type="button" class="usa-button usa-button--unstyled close-overlay text-black width-auto"  tabindex="1">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
             </button>
        </div>

        

<div class="citation-text-block">
  <div class="citation-text margin-bottom-2"></div>
  <ul class="usa-list usa-list--unstyled display-inline-flex flex-justify width-full flex-align-center">
      <li>
        <button
          class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center copy-button dialog-focus"
          data-ga-category="save_share"
          data-ga-action="cite"
          data-ga-label="copy"
          tabindex="2">
            <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                <use xlink:href="/static/img/sprite.svg#content_copy"></use>
            </svg>
            <span>Copy</span>
        </button>
      </li>
      <li>
          <a
              href="#"
              role="button"
              class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center export-button"
              data-ga-category="save_share"
              data-ga-action="cite"
              data-ga-label="download"
              title="Download a file for external citation management software"
              tabindex="3">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                </svg>
                <span class="display-none mobile-lg:display-inline">Download .nbib</span>
                <span class="display-inline mobile-lg:display-none">.nbib</span>
            </a>
      </li>
      <li>
          

<div class="display-inline-flex flex-align-center">
  <label class="usa-label margin-top-0">Format:</label>
  <select aria-label="Format" class="usa-select citation-style-selector padding-1 margin-top-0 border-0 padding-right-4" tabindex="4" >
    
      <option data-style-url-name="ama"
              value="AMA"
              >
        AMA
      </option>
    
      <option data-style-url-name="apa"
              value="APA"
              >
        APA
      </option>
    
      <option data-style-url-name="mla"
              value="MLA"
              >
        MLA
      </option>
    
      <option data-style-url-name="nlm"
              value="NLM"
              selected="selected">
        NLM
      </option>
    
  </select>
</div>
      </li>
  </ul>
</div>
    </div>
</div>

        <div class="overlay" role="dialog" hidden>
  <div id="collections-action-dialog" class="dialog collections-dialog" aria-hidden="true">
   <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
        <h2 class="usa-modal__heading margin-0">Add to Collections</h2>
    </div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="usa-form maxw-full collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/list-existing-collections/"
      data-add-to-existing-collection-url="/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

    <input type="hidden" name="csrfmiddlewaretoken" value="AVDe4Rx7XXJaIhdLxLnZ5Sa0eeTlNeXuFLcf2Dv25kwklGeG2fAxIU96IOuSj1mF">

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-new"
            class="usa-radio__input usa-radio__input--tile collections-new  margin-top-0"
            name="collections"
            value="new"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_new" />
            <label class="usa-radio__label" for="collections-action-dialog-new">Create a new collection</label>
        </div>
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-existing"
            class="usa-radio__input usa-radio__input--tile collections-existing"
            name="collections"
            value="existing"
            checked="true"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_existing" />
            <label class="usa-radio__label" for="collections-action-dialog-existing">Add to an existing collection</label>
        </div>
    </fieldset>

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="action-panel-control-wrap new-collections-controls">
           <label for="collections-action-dialog-add-to-new" class="usa-label margin-top-0">
                Name your collection
               <abbr title="required" class="usa-hint usa-hint--required text-no-underline">*</abbr>
          </label>
          <input
            type="text"
            name="add-to-new-collection"
            id="collections-action-dialog-add-to-new"
            class="usa-input collections-action-add-to-new"
            pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
            maxlength=""
            data-ga-category="collections_button"
            data-ga-action="create_collection"
            data-ga-label="non_favorties_collection"
            required
          />
        </div>
        <div class="action-panel-control-wrap existing-collections-controls">
             <label for="collections-action-dialog-add-to-existing" class="usa-label margin-top-0">
                Choose a collection
              </label>
              <select id="collections-action-dialog-add-to-existing"
                      class="usa-select collections-action-add-to-existing"
                      data-ga-category="collections_button"
                      data-ga-action="select_collection"
                      data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
              </select>
              <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
                Unable to load your collection due to an error<br>
                <a href="#">Please try again</a>
              </div>
        </div>
    </fieldset>

    <div class="display-inline-flex">
        <button class="usa-button margin-top-0 action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
          Add
        </button>
        <button class="usa-button usa-button--outline margin-top-0 action-panel-cancel"
                aria-label="Close 'Add to Collections' panel"
                ref="linksrc=close_collections_panel"
                data-ga-category="collections_button"
                data-ga-action="click"
                data-ga-label="cancel">
          Cancel
        </button>
    </div>
</form>
    </div>
  </div>
</div>

        

      </div>
    </div>
  </div>



        
    
    

<footer class="ncbi-footer ncbi-dark-background " >
    
        <div class="ncbi-footer__icon-section">
            <div class="ncbi-footer__social-header">
                Follow NCBI
            </div>

            <div class="grid-container ncbi-footer__ncbi-social-icons-container">
                
                    <a href="https://twitter.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="40"
                             height="40"
                             viewBox="0 0 40 40"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on X (formerly known as Twitter)</span>
                    </a>
                

                
                    <a href="https://www.facebook.com/ncbi.nlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="16"
                             height="29"
                             focusable="false"
                             aria-hidden="true"
                             viewBox="0 0 16 29"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg">
                            <path d="M3.8809 21.4002C3.8809 19.0932 3.8809 16.7876 3.8809 14.478C3.8809 14.2117 3.80103 14.1452 3.54278 14.1492C2.53372 14.1638 1.52334 14.1492 0.514288 14.1598C0.302626 14.1598 0.248047 14.0972 0.248047 13.8936C0.256034 12.4585 0.256034 11.0239 0.248047 9.58978C0.248047 9.37013 0.302626 9.30224 0.528931 9.3049C1.53798 9.31688 2.54837 9.3049 3.55742 9.31555C3.80103 9.31555 3.8809 9.26097 3.87957 9.00272C3.87158 8.00565 3.85428 7.00592 3.90753 6.00884C3.97142 4.83339 4.31487 3.73115 5.04437 2.78467C5.93095 1.63318 7.15699 1.09005 8.56141 0.967577C10.5582 0.79319 12.555 0.982221 14.5518 0.927641C14.7102 0.927641 14.7462 0.99287 14.7449 1.13664C14.7449 2.581 14.7449 4.02668 14.7449 5.47104C14.7449 5.67604 14.6517 5.68669 14.4946 5.68669C13.4523 5.68669 12.4113 5.68669 11.3703 5.68669C10.3506 5.68669 9.92057 6.10868 9.90593 7.13904C9.89661 7.7647 9.91525 8.39303 9.89794 9.01869C9.88995 9.26364 9.96583 9.31822 10.2015 9.31688C11.7204 9.30623 13.2393 9.31688 14.7595 9.3049C15.0257 9.3049 15.0723 9.3728 15.0444 9.62439C14.89 10.9849 14.7515 12.3467 14.6144 13.7085C14.5691 14.1571 14.5785 14.1585 14.1458 14.1585C12.8386 14.1585 11.5313 14.1665 10.2254 14.1518C9.95119 14.1518 9.89794 14.2317 9.89794 14.4899C9.90593 19.0799 9.89794 23.6752 9.91125 28.2612C9.91125 28.5674 9.8407 28.646 9.53186 28.6433C7.77866 28.6273 6.02414 28.6366 4.27094 28.634C3.82499 28.634 3.87158 28.6992 3.87158 28.22C3.87602 25.9472 3.87913 23.6739 3.8809 21.4002Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on Facebook</span>
                    </a>
                

                
                    <a href="https://www.linkedin.com/company/ncbinlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="25"
                             height="23"
                             viewBox="0 0 26 24"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M14.6983 9.98423C15.6302 9.24808 16.5926 8.74754 17.6762 8.51991C19.673 8.09126 21.554 8.30824 23.1262 9.7526C24.2351 10.7723 24.7529 12.1115 25.0165 13.5612C25.1486 14.3363 25.2105 15.1218 25.2015 15.9081C25.2015 18.3043 25.2015 20.6898 25.2082 23.0806C25.2082 23.3468 25.1549 23.444 24.8621 23.4414C23.1297 23.4272 21.3992 23.4272 19.6704 23.4414C19.4041 23.4414 19.3429 23.3588 19.3442 23.1019C19.3535 20.5194 19.3442 17.9368 19.3442 15.3543C19.3442 14.0005 18.3258 12.9448 17.0266 12.9488C15.7273 12.9528 14.6983 14.0071 14.6983 15.361C14.6983 17.9328 14.6917 20.5047 14.6983 23.0753C14.6983 23.3708 14.6198 23.444 14.3296 23.4427C12.6185 23.4294 10.9079 23.4294 9.19779 23.4427C8.93155 23.4427 8.86099 23.3735 8.86232 23.1086C8.8783 19.7619 8.88628 16.4144 8.88628 13.066C8.88628 11.5688 8.87874 10.0708 8.86365 8.57182C8.86365 8.3575 8.90758 8.27896 9.14054 8.28029C10.9048 8.29094 12.6687 8.29094 14.4321 8.28029C14.6464 8.28029 14.6983 8.34818 14.6983 8.54653C14.6903 9.00047 14.6983 9.45441 14.6983 9.98423Z">
                            </path>
                            <path d="M6.55316 15.8443C6.55316 18.2564 6.55316 20.6699 6.55316 23.082C6.55316 23.3629 6.48127 23.4388 6.19906 23.4374C4.47737 23.4241 2.75568 23.4241 1.03399 23.4374C0.767751 23.4374 0.69986 23.3629 0.701191 23.1006C0.709178 18.2648 0.709178 13.4281 0.701191 8.59053C0.701191 8.34026 0.765089 8.27237 1.01669 8.2737C2.74991 8.28435 4.48048 8.28435 6.20838 8.2737C6.47462 8.2737 6.5465 8.33627 6.54517 8.6065C6.54783 11.0186 6.55316 13.4308 6.55316 15.8443Z">
                            </path>
                            <path d="M3.65878 0.243898C5.36804 0.243898 6.58743 1.45529 6.58743 3.1406C6.58743 4.75801 5.32145 5.95742 3.60819 5.96807C3.22177 5.97614 2.83768 5.90639 2.47877 5.76299C2.11985 5.61959 1.79344 5.40546 1.51897 5.13334C1.24449 4.86123 1.02755 4.53668 0.881058 4.17902C0.734563 3.82136 0.661505 3.43788 0.666231 3.05141C0.67555 1.42601 1.9362 0.242566 3.65878 0.243898Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on LinkedIn</span>
                    </a>
                

                
                    <a href="https://github.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="28"
                             height="27"
                             viewBox="0 0 28 28"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M16.7228 20.6334C17.5057 20.5527 18.2786 20.3944 19.0301 20.1608C21.3108 19.4193 22.5822 17.8259 22.963 15.4909C23.1228 14.5112 23.1814 13.5287 22.9883 12.5437C22.8106 11.6423 22.4013 10.8028 21.8007 10.1076C21.7526 10.0605 21.7197 10 21.7064 9.934C21.6931 9.86799 21.7 9.79952 21.7262 9.73748C22.0856 8.6206 21.9711 7.51969 21.601 6.42677C21.582 6.3497 21.5345 6.2827 21.468 6.23923C21.4016 6.19577 21.3211 6.17906 21.2429 6.19248C20.7329 6.21649 20.2313 6.33051 19.7611 6.52928C19.1103 6.7908 18.4899 7.12198 17.9104 7.51703C17.84 7.56996 17.7581 7.60551 17.6713 7.62078C17.5846 7.63605 17.4954 7.6306 17.4112 7.60489C15.2596 7.05882 13.0054 7.06203 10.8554 7.61421C10.7806 7.63586 10.7018 7.63967 10.6253 7.62534C10.5487 7.611 10.4766 7.57892 10.4148 7.53167C9.64788 7.03247 8.85171 6.58918 7.96368 6.33359C7.65781 6.24338 7.34123 6.19458 7.02239 6.18849C6.94879 6.17986 6.87462 6.19893 6.81432 6.242C6.75402 6.28507 6.71191 6.34904 6.69621 6.42145C6.32342 7.51437 6.2209 8.61527 6.56307 9.73348C6.59635 9.84264 6.64694 9.93316 6.54177 10.0516C5.47666 11.2604 5.09988 12.6834 5.19574 14.2676C5.2663 15.4244 5.46201 16.5466 6.01454 17.5769C6.84399 19.1171 8.21664 19.9119 9.85158 20.3352C10.3938 20.4706 10.9444 20.5698 11.4998 20.632C11.5384 20.7492 11.4506 20.7798 11.408 20.8291C11.1734 21.1179 10.9894 21.4441 10.8634 21.7942C10.7622 22.0458 10.8315 22.4039 10.6065 22.5516C10.263 22.7766 9.83827 22.8485 9.42421 22.8871C8.17936 23.0056 7.26471 22.4877 6.6283 21.4348C6.25552 20.8184 5.76956 20.3325 5.08523 20.0663C4.76981 19.9325 4.42139 19.8967 4.08537 19.9638C3.7898 20.029 3.73788 20.1901 3.93891 20.4111C4.03639 20.5234 4.14989 20.6207 4.27575 20.6999C4.9796 21.1318 5.51717 21.7884 5.80152 22.5636C6.37002 23.9973 7.48039 24.5697 8.93825 24.6323C9.43741 24.6575 9.93768 24.615 10.4254 24.5058C10.5892 24.4672 10.6531 24.4872 10.6517 24.6762C10.6451 25.4936 10.6637 26.3123 10.6517 27.131C10.6517 27.6635 10.1684 27.9297 9.58663 27.7393C8.17396 27.2671 6.84977 26.5631 5.66838 25.656C2.59555 23.2891 0.720966 20.1861 0.217704 16.3376C-0.357453 11.9127 0.911353 8.00824 3.98551 4.73881C6.11909 2.42656 8.99932 0.939975 12.1203 0.540191C16.5351 -0.0601815 20.4347 1.14323 23.7232 4.16373C26.2449 6.47869 27.724 9.37672 28.1048 12.7726C28.5828 17.0325 27.3686 20.7945 24.4768 23.9827C22.9762 25.6323 21.0956 26.8908 18.9982 27.6488C18.8783 27.6927 18.7585 27.738 18.636 27.7726C18.0356 27.9404 17.6189 27.6395 17.6189 27.0098C17.6189 25.7452 17.6308 24.4806 17.6295 23.2159C17.6329 22.9506 17.6128 22.6856 17.5696 22.4238C17.4325 21.6664 17.3419 21.484 16.7228 20.6334Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on GitHub</span>
                    </a>
                

                
                    <a href="https://ncbiinsights.ncbi.nlm.nih.gov/"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="26"
                             height="26"
                             viewBox="0 0 27 27"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M23.7778 26.4574C23.1354 26.3913 22.0856 26.8024 21.636 26.3087C21.212 25.8444 21.4359 24.8111 21.324 24.0347C19.9933 14.8323 14.8727 8.80132 6.09057 5.85008C4.37689 5.28406 2.58381 4.99533 0.779072 4.99481C0.202773 4.99481 -0.0229751 4.83146 0.00455514 4.21479C0.0660406 3.08627 0.0660406 1.95525 0.00455514 0.826734C-0.0413285 0.0815827 0.259669 -0.0193618 0.896534 0.00266238C6.96236 0.222904 12.3693 2.24179 16.9889 6.16209C22.9794 11.2478 26.1271 17.7688 26.4372 25.648C26.4629 26.294 26.3179 26.5271 25.6609 26.4684C25.0827 26.417 24.4991 26.4574 23.7778 26.4574Z">
                            </path>
                            <path d="M14.8265 26.441C14.0924 26.441 13.2371 26.6795 12.6626 26.3786C12.0092 26.0372 12.3781 25.0644 12.246 24.378C11.1154 18.5324 6.6849 14.5497 0.74755 14.1001C0.217135 14.0615 -0.0104482 13.9422 0.0134113 13.3659C0.0519536 12.1454 0.0482829 10.9213 0.0134113 9.69524C-0.00127145 9.14464 0.196946 9.03268 0.703502 9.04736C9.21217 9.27128 16.5994 16.2511 17.2804 24.7231C17.418 26.4446 17.418 26.4446 15.6579 26.4446H14.832L14.8265 26.441Z">
                            </path>
                            <path d="M3.58928 26.4555C2.64447 26.4618 1.73584 26.0925 1.06329 25.4289C0.39073 24.7653 0.00933763 23.8617 0.0030097 22.9169C-0.00331824 21.9721 0.365937 21.0635 1.02954 20.3909C1.69315 19.7184 2.59675 19.337 3.54156 19.3306C4.48637 19.3243 5.39499 19.6936 6.06755 20.3572C6.7401 21.0208 7.1215 21.9244 7.12782 22.8692C7.13415 23.814 6.7649 24.7226 6.10129 25.3952C5.43768 26.0677 4.53409 26.4491 3.58928 26.4555Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI RSS feed</span>
                    </a>
                
            </div>
        </div>
    

    <div data-testid="gridContainer"
         class="grid-container ncbi-footer__container">
        <div class="grid-row ncbi-footer__main-content-container"
             data-testid="grid">
            
                <div class="ncbi-footer__column">
                    
                        <p class="ncbi-footer__circled-icons-heading">
                            Connect with NLM
                        </p>
                    

                    <div class="ncbi-footer__circled-icons-list">
                        
                            <a href=https://twitter.com/nlm_nih class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="32"
                                     height="32"
                                     viewBox="0 0 40 40"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on X (formerly known as Twitter)</span>
                            </a>
                        

                        
                            <a href=https://www.facebook.com/nationallibraryofmedicine class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="13"
                                     height="24"
                                     viewBox="0 0 13 24"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M4.11371 23.1369C4.11371 23.082 4.11371 23.0294 4.11371 22.9745V12.9411H0.817305C0.6709 12.9411 0.670898 12.9411 0.670898 12.8016C0.670898 11.564 0.670898 10.3287 0.670898 9.09341C0.670898 8.97903 0.705213 8.95158 0.815017 8.95158C1.8673 8.95158 2.91959 8.95158 3.97417 8.95158H4.12057V8.83263C4.12057 7.8055 4.12057 6.7738 4.12057 5.74897C4.1264 4.92595 4.31387 4.11437 4.66959 3.37217C5.12916 2.38246 5.94651 1.60353 6.95717 1.1921C7.64827 0.905008 8.3913 0.764035 9.13953 0.778051C10.0019 0.791777 10.8644 0.830666 11.7268 0.860404C11.8869 0.860404 12.047 0.894717 12.2072 0.90158C12.2964 0.90158 12.3261 0.940469 12.3261 1.02968C12.3261 1.5421 12.3261 2.05452 12.3261 2.56465C12.3261 3.16857 12.3261 3.7725 12.3261 4.37642C12.3261 4.48165 12.2964 4.51367 12.1912 4.51138C11.5369 4.51138 10.8804 4.51138 10.2261 4.51138C9.92772 4.51814 9.63058 4.5526 9.33855 4.61433C9.08125 4.6617 8.84537 4.78881 8.66431 4.97766C8.48326 5.16652 8.3662 5.40755 8.32972 5.66661C8.28476 5.89271 8.26027 6.1224 8.25652 6.35289C8.25652 7.19014 8.25652 8.02969 8.25652 8.86923C8.25652 8.89439 8.25652 8.91955 8.25652 8.95615H12.0219C12.1797 8.95615 12.182 8.95616 12.1614 9.10714C12.0768 9.76596 11.9876 10.4248 11.9029 11.0813C11.8312 11.6319 11.7626 12.1824 11.697 12.733C11.6719 12.9434 11.6787 12.9434 11.4683 12.9434H8.26338V22.899C8.26338 22.979 8.26338 23.0591 8.26338 23.1392L4.11371 23.1369Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on Facebook</span>
                            </a>
                        

                        
                            <a href=https://www.youtube.com/user/NLMNIH class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="21"
                                     height="15"
                                     viewBox="0 0 21 15"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M19.2561 1.47914C18.9016 1.15888 18.5699 0.957569 17.2271 0.834039C15.5503 0.678484 13.2787 0.655608 11.563 0.65332H9.43556C7.71987 0.65332 5.4483 0.678484 3.77151 0.834039C2.43098 0.957569 2.097 1.15888 1.74242 1.47914C0.813665 2.32097 0.619221 4.62685 0.598633 6.89384C0.598633 7.31781 0.598633 7.74101 0.598633 8.16345C0.626084 10.4121 0.827391 12.686 1.74242 13.521C2.097 13.8412 2.4287 14.0425 3.77151 14.1661C5.4483 14.3216 7.71987 14.3445 9.43556 14.3468H11.563C13.2787 14.3468 15.5503 14.3216 17.2271 14.1661C18.5676 14.0425 18.9016 13.8412 19.2561 13.521C20.1712 12.6929 20.3725 10.451 20.3999 8.22064C20.3999 7.74025 20.3999 7.25986 20.3999 6.77946C20.3725 4.54907 20.1689 2.30724 19.2561 1.47914ZM8.55942 10.5311V4.65201L13.5601 7.50005L8.55942 10.5311Z"
                                          fill="white" />
                                </svg>
                                <span class="usa-sr-only">NLM on YouTube</span>
                            </a>
                        
                    </div>
                </div>
            

            
                <address class="ncbi-footer__address ncbi-footer__column">
                    
        <p>
            <a class="usa-link usa-link--external"
            href="https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/%4038.9959508,
            -77.101021,17z/data%3D!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb%3A0x19156f88b27635b8!8m2!3d38.9959508!
            4d-77.0988323"
            rel="noopener noreferrer" target="_blank">National Library of Medicine
            <br/> 8600 Rockville Pike<br/> Bethesda, MD 20894</a>
        </p>
    
                </address>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/web_policies.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Web Policies
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            FOIA
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS Vulnerability Disclosure
        

        
    </a>


                        </li>
                    
                </ul>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://support.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Help
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/accessibility.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Accessibility
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/careers/careers.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Careers
        

        
    </a>


                        </li>
                    
                </ul>
            
        </div>

        
            <div class="grid-row grid-col-12" data-testid="grid">
                <ul class="ncbi-footer__bottom-links-list">
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NLM
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NIH
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.hhs.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.usa.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            USA.gov
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        
    </div>
</footer>

    


        
        
    
  <script  type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/pinger/pinger.js"> </script>


    
        

<button class="back-to-top" data-ga-category="pagination" data-ga-action="back_to_top">
    <label>Back to Top</label>
    <svg class="usa-icon order-0" aria-hidden="true" focusable="false" role="img">
        <use xlink:href="/static/img/sprite.svg#arrow_upward"></use>
    </svg>
</button>
    


        
    
    
    
        
    <script type="application/javascript">
    window.ncbi = window.ncbi || {};
    window.ncbi.pmc = window.ncbi.pmc || {};
    window.ncbi.pmc.options = {
        logLevel: 'INFO',
        
        staticEndpoint: '/static/',
        
        citeCookieName: 'pmc-cf',
    };
</script>
    <script type="module" crossorigin="" src="/static/assets/base-133c6271.js"></script>
    
    <script type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/jquery/jquery-3.6.0.min.js">&#xA0;</script>
    <script type="text/javascript">
        jQuery.getScript("https://cdn.ncbi.nlm.nih.gov/core/alerts/alerts.js", function () {
            galert(['div.nav_and_browser', 'div.header', '#universal_header', '.usa-banner', 'body > *:nth-child(1)'])
        });
    </script>


    <script type="text/javascript">var exports = {};</script>
     <script src="/static/CACHE/js/output.13b077bc3ffd.js"></script>

    <script type="module" crossorigin="" src="/static/assets/article-44d04358.js"></script>
    
    

    </body>
</html>
